https://gpcardio.org/en/
https://gpcardio.org/en/2014-05-28_practical-guidance-for-primary-care-physicians-on-statin-use-in-people-at-risk-of-getting-diabetes/
https://gpcardio.org/en/2015-01-07_the-epccs-stroke-prevention-in-atrial-fibrillation-guidance-document-1/
https://gpcardio.org/en/2015-09-29_lively-debate-at-annual-epccs-clinical-masterclass-to-yield-practical-guidance/
https://gpcardio.org/en/2015-10-02_what-s-the-evidence-base-for-blood-pressure-modification-in-the-guideline-updates/
https://gpcardio.org/en/2015-10-02_what-s-the-evidence-base-for-health-behaviour-modification-in-the-guideline-updates/
https://gpcardio.org/en/2015-10-12_what-s-the-evidence-base-for-lipid-modification-in-the-guideline-updates/
https://gpcardio.org/en/2015-10-14_what-s-the-evidence-base-for-heart-failure-diagnosis-and-management-in-the-guideline-updates/
https://gpcardio.org/en/2016-03-15_what-is-the-evidence-base-for-lipid-modification-in-the-guidelines-updates/
https://gpcardio.org/en/2016-04-15_identifying-and-treating-patients-with-true-hypertension/
https://gpcardio.org/en/2016-05-26_the-evidence-base-for-health-behaviour-changes/
https://gpcardio.org/en/2016-09-06_epccs-consensus-guidance-on-stroke-prevention-in-atrial-fibrillation-spaf-in-primary-care/
https://gpcardio.org/en/2016-09-28_epccs-guidance-documents/
https://gpcardio.org/en/2017-03-30_guidance-on-changing-health-behaviours-what-is-the-evidence-what-s-recommended-and-do-i-agree/
https://gpcardio.org/en/2017-04-20_atrial-fibrillation-management-what-do-the-guidelines-say-and-what-are-the-implications-for-primary-care/
https://gpcardio.org/en/2017-04-20_controversies-in-hypertension-what-are-the-implication-of-sprint-in-the-context-of-recent-treatment-trials/
https://gpcardio.org/en/2017-04-20_controversies-in-lipids-is-the-role-of-statins-now-clear-are-there-alternatives-and-what-s-in-the-pipeline/
https://gpcardio.org/en/2017-04-20_guidance-on-changing-health-behaviours-what-is-the-evidence-what-s-recommended-and-do-i-agree/
https://gpcardio.org/en/2017-04-20_lipid-management-what-do-the-guidelines-say-and-what-are-the-implications-for-primary-care/
https://gpcardio.org/en/2017-04-20_what-s-the-new-evidence-base-for-heart-failure-diagnosis-management/
https://gpcardio.org/en/2017-06-05_ingredients-of-effective-strategies-to-stimulate-behaviour-change/
https://gpcardio.org/en/2017-06-22_how-do-the-latest-guideline-changes-affect-management-of-dyslipidaemia-in-primary-care/
https://gpcardio.org/en/2017-07-01_epccs-heart-failure-guidance-published-as-clinical-intelligence-in-br-j-gen-prac/
https://gpcardio.org/en/2017-07-18_heart-failure-diagnosis-and-management-varies-substantially-across-european-countries/
https://gpcardio.org/en/2017-09-13_what-can-be-learned-from-the-latest-hypertension-trials/
https://gpcardio.org/en/2017-12-10_epccs-practical-guidance-on-heart-failure-diagnosis-and-management-in-primary-care/
https://gpcardio.org/en/2018-02-06_how-can-epccs-expand-its-membership/
https://gpcardio.org/en/2018-02-06_how-can-the-epccs-better-engage-with-primary-care-physicians-in-various-european-countries-regarding-cardiovascular-disease-education/
https://gpcardio.org/en/2018-02-19_chronicke-srdcove-zlyhavanie/
https://gpcardio.org/en/2018-02-19_prevencia-cievnej-mozgovej-prihody-u-pacientov-s-fibrilaciou-predsieni/
https://gpcardio.org/en/2018-02-19_практична-настанова-по-діагностиці-та-менеджменту-серцевої-недостатності-в-системі-первинної-медичної-допомоги/
https://gpcardio.org/en/2018-02-22_stimulating-health-behaviour-changes-to-reduce-cardiovascular-risk-in-primary-care/
https://gpcardio.org/en/2018-02-25_slides-organisation-of-primary-care-in-the-netherlands/
https://gpcardio.org/en/2018-02-26_netherlands-cardiovascular-primary-care-overview/
https://gpcardio.org/en/2018-02-26_slides-organisation-of-primary-care-in-slovakia/
https://gpcardio.org/en/2018-02-26_slides-primary-care-in-bulgaria-nagpb/
https://gpcardio.org/en/2018-02-26_slovakia-cardiovascular-primary-care-overview/
https://gpcardio.org/en/2018-02-27_slides-cardiovascular-primary-care-in-spain/
https://gpcardio.org/en/2018-02-27_slides-organisation-of-primary-care-in-portugal/
https://gpcardio.org/en/2018-02-28_bulgaria-cardiovascular-primary-care/
https://gpcardio.org/en/2018-02-28_portugal-cardiovascular-primary-care-overview/
https://gpcardio.org/en/2018-02-28_slides-cardiovascular-primary-care-in-france/
https://gpcardio.org/en/2018-02-28_spain-cardiovascular-primary-care-overview/
https://gpcardio.org/en/2018-03-01_france-cardiovascular-primary-care-overview/
https://gpcardio.org/en/2018-03-01_greece-cardiovascular-primary-care-overview/
https://gpcardio.org/en/2018-03-01_romania-cardiovascular-primary-care-overview/
https://gpcardio.org/en/2018-03-01_slides-cardiovascular-primary-care-in-greece/
https://gpcardio.org/en/2018-03-01_slides-cardiovascular-primary-care-in-romania/
https://gpcardio.org/en/2018-03-02_germany-cardiovascular-primary-care-overview/
https://gpcardio.org/en/2018-03-02_slides-cardiovascular-primary-care-in-germany/
https://gpcardio.org/en/2018-03-13_погоджена-настанова-epccs-щодо-профілактики-інсульту-при-фібриляції-передсердь-в-системі-надання-первинної-медичної-допомоги/
https://gpcardio.org/en/2018-03-27_lower-extremity-artery-disease-a-neglected-major-cv-disease/
https://gpcardio.org/en/2018-03-27_stimularea-schimbarilor-de-comportament-in-domeniul-sanatatii-pentru-a-reduce-riscul-cardiovascular-in-asistenta-medicala-primara/
https://gpcardio.org/en/2018-03-28_diabetes-and-vascular-disease-epidemiology-and-management-options/
https://gpcardio.org/en/2018-04-04_managing-elevated-lipids-and-statins-the-good-the-bad-and-the-ugly/
https://gpcardio.org/en/2018-04-04_slides-hypertension-can-we-agree-on-diagnostic-and-therapeutic-thresholds/
https://gpcardio.org/en/2018-04-04_slides-lipid-lowering-the-evidence-the-guidelines-the-clinical-reality/
https://gpcardio.org/en/2018-04-04_slides-lower-extremity-artery-disease-a-neglected-major-cv-disease-diagnose-and-clinical-management-in-primary-care/
https://gpcardio.org/en/2018-04-04_slides-managing-complex-heart-failure-a-specialist-view-of-the-primary-secondary-interface/
https://gpcardio.org/en/2018-04-04_slides-managing-heart-failure-in-primary-care-the-gp-perspective/
https://gpcardio.org/en/2018-04-04_slides-practical-workshop-on-abpm/
https://gpcardio.org/en/2018-04-04_slides-type-2-diabetes-cardiovascular-disease-update/
https://gpcardio.org/en/2018-04-10_complexities-of-managing-heart-failure-in-primary-care/
https://gpcardio.org/en/2018-04-10_hypertension-can-we-agree-on-diagnostic-and-therapeutic-thresholds/
https://gpcardio.org/en/2018-04-24_management-of-cv-risk-that-comes-with-t2dm-in-light-of-novel-treatment-options/
https://gpcardio.org/en/2018-05-16_cardiovascular-primary-care-in-italy/
https://gpcardio.org/en/2018-05-16_slides-primary-care-in-italy/
https://gpcardio.org/en/2018-05-22_lipid-lowering-the-evidence-the-guidelines-the-clinical-reality/
https://gpcardio.org/en/2018-06-15_semergen-la-sociedad-decana-de-la-medicina-de-familia-en-espana/
https://gpcardio.org/en/2018-06-15_semergen-sociedad-espanola-de-medicos-de-atencion-primaria/
https://gpcardio.org/en/2018-06-19_spain-epccs-introduction/
https://gpcardio.org/en/2018-07-18_complexities-of-managing-heart-failure/
https://gpcardio.org/en/2018-08-16_hypertension-can-we-agree-on-diagnostic-and-therapeutic-thresholds/
https://gpcardio.org/en/2018-08-22_managing-elevated-lipids-in-primary-care/
https://gpcardio.org/en/2018-10-22_general-practitioner-in-denmark/
https://gpcardio.org/en/2018-10-22_managementul-dislipidemiei-in-asistenta-medicala-primara/
https://gpcardio.org/en/2018-10-22_praktican-vodic-za-dijagnostikovanje-i-lecenje-srcane-insuficijencije-u-primarnoj-zdravstvenoj-zastiti-pzz/
https://gpcardio.org/en/2018-10-22_stimulacija-promene-zivotnog-stila-u-cilju-smanjenja-kardiovaskularnog-rizika-u-pzz/
https://gpcardio.org/en/2018-10-23_prevention-of-cardiovascular-noncommunicable-disease-in-primary-care-in-russia/
https://gpcardio.org/en/2018-10-25_lecenje-povisenih-lipida-u-primarnoj-zdravstvenoj-zastiti-pzz/
https://gpcardio.org/en/2018-10-30_шляхи-стимулювання-модифікації-способу-життя-з-метою-зменшення-серцево-судинного-ризику-на-первинній-ланці-медичної-допомоги/
https://gpcardio.org/en/2018-12-03_primary-cardiovascular-care-in-serbia-english/
https://gpcardio.org/en/2018-12-04_primary-cardiovascular-care-in-czech-republic-czech/
https://gpcardio.org/en/2018-12-04_primary-cardiovascular-care-in-czech-republic-english/
https://gpcardio.org/en/2018-12-04_primary-cardiovascular-care-in-montenegro-english/
https://gpcardio.org/en/2018-12-04_primary-cardiovascular-care-in-serbia-serbian/
https://gpcardio.org/en/2018-12-04_primary-cardiovascular-care-in-ukraine-english/
https://gpcardio.org/en/2018-12-04_primary-cardiovascular-care-in-ukraine-ukrainian/
https://gpcardio.org/en/2018-12-05_primary-cardiovascular-care-in-belgium-english/
https://gpcardio.org/en/2018-12-05_primary-cardiovascular-care-in-belgium-flemish/
https://gpcardio.org/en/2018-12-05_primary-cardiovascular-care-in-poland-english/
https://gpcardio.org/en/2018-12-05_primary-cardiovascular-care-in-poland-polish/
https://gpcardio.org/en/2018-12-05_primary-cardiovascular-care-in-slovakia-english/
https://gpcardio.org/en/2018-12-05_primary-cardiovascular-care-in-slovakia-slovak/
https://gpcardio.org/en/2018-12-07_primary-cardiovascular-care-in-germany-english/
https://gpcardio.org/en/2018-12-07_primary-cardiovascular-care-in-germany-german/
https://gpcardio.org/en/2018-12-10_primary-cardiovascular-care-in-ireland-english/
https://gpcardio.org/en/2018-12-10_primary-cardiovascular-care-in-turkey-turkish/
https://gpcardio.org/en/2018-12-13_primary-cardiovascular-care-in-turkey-english/
https://gpcardio.org/en/2018-12-17_primary-cardiovascular-care-in-denmark-danish/
https://gpcardio.org/en/2018-12-17_primary-cardiovascular-care-in-denmark-english/
https://gpcardio.org/en/2018-12-17_primary-cardiovascular-care-in-montenegro-montenegrin/
https://gpcardio.org/en/2018-12-17_primary-cardiovascular-care-in-romania-romanian/
https://gpcardio.org/en/2018-12-17_primary-cardiovascular-care-in-spain-english/
https://gpcardio.org/en/2018-12-17_primary-cardiovascular-care-in-spain-spanish/
https://gpcardio.org/en/2018-12-18_slides-take-home-messages-of-epccs-guidance-on-managing-elevated-lipids-in-primary-care/
https://gpcardio.org/en/2019-01-10_primary-cardiovascular-care-in-spain-english/
https://gpcardio.org/en/2019-01-10_primary-cardiovascular-care-in-spain-spanish/
https://gpcardio.org/en/2019-02-07_epccs-society-what-is-available-for-members/
https://gpcardio.org/en/2019-02-25_current-management-of-diabetes-and-cardiovascular-risk-in-primary-care/
https://gpcardio.org/en/2019-03-28_diabetes-and-cardiovascular-risk/
https://gpcardio.org/en/2019-03-28_how-to-deal-with-the-challenges-of-multimorbidity-in-general-practice/
https://gpcardio.org/en/2019-03-28_update-on-stroke-prevention-in-atrial-fibrillation/
https://gpcardio.org/en/2019-04-02_slides-complexities-of-managing-heart-failure/
https://gpcardio.org/en/2019-04-02_slides-cvd-and-mental-health/
https://gpcardio.org/en/2019-04-02_slides-diabetes-and-cardiovascular-risk/
https://gpcardio.org/en/2019-04-02_slides-multimorbidity-cv-disease-and-polypharmacy/
https://gpcardio.org/en/2019-04-02_slides-recent-updates-to-the-international-hypertension-guidelines-where-do-they-vary-and-what-should-we-agree-in-primary-care/
https://gpcardio.org/en/2019-04-02_slides-update-on-stroke-prevention-in-atrial-fibrillation/
https://gpcardio.org/en/2019-04-02_slides-what-s-the-evidence-that-diabetes-is-linked-to-cvd-risk/
https://gpcardio.org/en/2019-04-03_complexities-of-managing-heart-failure/
https://gpcardio.org/en/2019-04-24_recent-updates-to-the-international-hypertension-guidelines-where-do-they-vary-and-what-should-we-agree-in-primary-care/
https://gpcardio.org/en/2019-04-25_education-exchange-guidance-and-interaction-during-epccs-summit-2019/
https://gpcardio.org/en/2019-05-02_slides-managing-diabetes-in-daily-cardiovascular-practice-a-multidisciplinary-approach/
https://gpcardio.org/en/2019-05-02_slides-targeting-cvd-in-diabetes-novel-strategies-to-tackle-the-risk/
https://gpcardio.org/en/2019-05-02_slides-type-2-diabetes-cv-outcomes-more-than-glucose-management-lessons-from-glp1-ra-trials/
https://gpcardio.org/en/2019-05-07_stroke-prevention-in-atrial-fibrillation/
https://gpcardio.org/en/2019-05-21_update-on-managing-cv-risk-in-diabetes-what-s-the-evidence/
https://gpcardio.org/en/2019-06-18_new-diagnostic-algorithm-and-therapeutic-options-in-hf-management/
https://gpcardio.org/en/2019-08-13_slides-take-home-messages-of-epccs-guidance-on-current-management-of-diabetes-and-cv-risk-in-primary-care/
https://gpcardio.org/en/2019-08-29_diagnosis-and-management-of-hypertension-in-primary-care/
https://gpcardio.org/en/2019-10-02_outreach-of-epccs-into-european-countries-what-s-in-store/
https://gpcardio.org/en/2019-10-03_epccs-and-primary-cv-care-in-serbia/
https://gpcardio.org/en/2019-10-03_epccs-and-primary-cv-care-in-slovakia-english/
https://gpcardio.org/en/2019-10-03_epccs-and-primary-cv-care-in-slovakia-slovak/
https://gpcardio.org/en/2019-10-03_epccs-and-primary-cv-care-in-spain-english/
https://gpcardio.org/en/2019-10-03_epccs-and-primary-cv-care-in-spain-spanish/
https://gpcardio.org/en/2019-10-03_how-epccs-aims-to-help-primary-care-physicians-across-europe-in-recognizing-and-managing-cv-risk-greek/
https://gpcardio.org/en/2019-10-09_how-epccs-aims-to-help-primary-care-physicians-across-europe-in-recognizing-and-managing-cv-risk-english/
https://gpcardio.org/en/2019-10-29_diagnosis-and-management-of-hypertension-in-primary-care-french-abstract/
https://gpcardio.org/en/2019-10-29_diagnosis-and-management-of-hypertension-in-primary-care-greek-abstract/
https://gpcardio.org/en/2019-10-29_diagnosis-and-management-of-hypertension-in-primary-care-ukrainian-abstract/
https://gpcardio.org/en/2019-10-29_dijagnostikovanje-i-lecenje-hipertenzije-u-primarnoj-zdravstvenoj-zastiti-serbian-abstract-of-epccs-guidance-on-hypertension/
https://gpcardio.org/en/2019-10-29_french-society-of-general-medicine-sfmg/
https://gpcardio.org/en/2019-10-29_greek-societies-involved-in-primary-care/
https://gpcardio.org/en/2019-11-04_epccs-and-primary-cv-care-in-france/
https://gpcardio.org/en/2019-11-04_epccs-and-primary-cv-care-in-ireland/
https://gpcardio.org/en/2019-11-04_epccs-and-primary-cv-care-in-poland-english/
https://gpcardio.org/en/2019-11-04_epccs-and-primary-cv-care-in-poland-polish/
https://gpcardio.org/en/2019-11-04_epccs-and-primary-cv-care-in-turkey/
https://gpcardio.org/en/2019-11-04_epccs-and-primary-cv-care-in-ukraine/
https://gpcardio.org/en/2019-11-12_heart-failure-and-comorbidities-kidney-disease-and-cancer/
https://gpcardio.org/en/2022-06-02_need-to-restart-and-catch-up-in-cvd-prevention-in-time-of-covid-19/
https://gpcardio.org/en/2023-10-24_traditional-chinese-medicine-compound-tongxinluo-and-clinical-outcomes-of-patients-with-acute-myocardial-infarction/
https://gpcardio.org/en/2023-11-02_pulsed-field-or-conventional-thermal-ablation-for-paroxysmal-atrial-fibrillation/
https://gpcardio.org/en/2023-11-23_transcatheter-aortic-valve-replacement-in-low-risk-patients-at-five-years/
https://gpcardio.org/en/2023-11-25_zibotentan-in-combination-with-dapagliflozin-compared-with-dapagliflozin-in-patients-with-chronic-kidney-disease-zenith-ckd/
https://gpcardio.org/en/2023-12-14_semaglutide-and-cardiovascular-outcomes-in-obesity-without-diabetes/
https://gpcardio.org/en/2023-12-21_a-placebo-controlled-trial-of-percutaneous-coronary-intervention-for-stable-angina/
https://gpcardio.org/en/2023-12-21_efficacy-of-ferric-carboxymaltose-in-heart-failure-with-iron-deficiency/
https://gpcardio.org/en/2023-12-28_restrictive-or-liberal-transfusion-strategy-in-myocardial-infarction-and-anemia/
https://gpcardio.org/en/2024-01-02_2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation/
https://gpcardio.org/en/2024-01-02_2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation/
https://gpcardio.org/en/2024-01-11_apixaban-for-stroke-prevention-in-subclinical-atrial-fibrillation/
https://gpcardio.org/en/2024-01-18_long-term-outcomes-of-resynchronization-defibrillation-for-heart-failure/
https://gpcardio.org/en/2024-02-13_implantable-hemodynamic-monitors-improve-survival-in-patients-with-heart-failure-and-reduced-ejection-fraction/
https://gpcardio.org/en/2024-02-20_an-aspirin-free-versus-dual-antiplatelet-strategy-for-coronary-stenting/
https://gpcardio.org/en/2024-02-20_safety-and-efficacy-of-ticagrelor-monotherapy-in-patients-with-acute-coronary-syndromes-undergoing-percutaneous-coronary-intervention/
https://gpcardio.org/en/2024-02-20_stopping-aspirin-within-1-month-after-stenting-for-ticagrelor-monotherapy-in-acute-coronary-syndrome/
https://gpcardio.org/en/2024-03-01_impact-of-bempedoic-acid-on-total-cardiovascular-events/
https://gpcardio.org/en/2024-03-02_intravascular-imaging-guided-coronary-drug-eluting-stent-implantation/
https://gpcardio.org/en/2024-03-18_global-shift-from-underweight-to-obesity-dominance-in-three-decades-across-generations/
https://gpcardio.org/en/2024-03-26_direct-oral-anticoagulants-for-stroke-prevention-in-patients-with-device-detected-atrial-fibrillation/
https://gpcardio.org/en/2024-04-01_transcatheter-or-surgical-aortic-valve-implantation/
https://gpcardio.org/en/2024-04-02_stratify-hf-a-european-collaboration-to-develop-an-ai-based-support-system-for-risk-stratification-and-early-detection-of-heart-failure/
https://gpcardio.org/en/2024-04-07_gamification-and-financial-incentives-to-increase-physical-activity-among-patients-at-elevated-cv-risk/
https://gpcardio.org/en/2024-04-08_enhanced-remote-medication-program-boosts-gdmt-prescriptions-for-high-cv-or-kidney-risk-in-t2d-patients/
https://gpcardio.org/en/2024-04-08_web-app-effective-in-determining-access-to-statins-without-a-prescription/
https://gpcardio.org/en/2024-04-16_2024-acc-expert-consensus-decision-pathway-for-treatment-of-heart-failure-with-reduced-ejection-fraction/
https://gpcardio.org/en/2024-04-18_beta-blockers-after-myocardial-infarction-and-preserved-ejection-fraction/
https://gpcardio.org/en/2024-04-18_microaxial-flow-pump-or-standard-care-in-infarct-related-cardiogenic-shock/
https://gpcardio.org/en/2024-04-18_semaglutide-in-patients-with-obesity-related-heart-failure-and-type-2-diabetes/
https://gpcardio.org/en/2024-04-25_empagliflozin-after-acute-myocardial-infarction/
https://gpcardio.org/en/2024-04-25_ffr-guided-complete-or-culprit-only-pci-in-patients-with-myocardial-infarction/
https://gpcardio.org/en/2024-04-27_semaglutide-versus-placebo-in-people-with-obesity-related-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2024-05-01_ticagrelor-or-clopidogrel-monotherapy-vs-dual-antiplatelet-therapy-after-percutaneous-coronary-intervention/
https://gpcardio.org/en/2024-05-02_apolipoprotein-a1-infusions-and-cardiovascular-outcomes-after-acute-myocardial-infarction/
https://gpcardio.org/en/2024-05-04_preventive-percutaneous-coronary-intervention-versus-optimal-medical-therapy-alone-for-the-treatment-of-vulnerable-atherosclerotic-coronary-plaques-pr/
https://gpcardio.org/en/2024-05-04_stratifyhf-providing-support-to-primary-care-in-early-diagnosis-of-heart-failure/
https://gpcardio.org/en/2024-05-06_the-stratifyhf-research-and-innovation-action/
https://gpcardio.org/en/2024-05-11_intravascular-ultrasound-guided-versus-angiography-guided-percutaneous-coronary-intervention-in-acute-coronary-syndromes-ivus-acs/
https://gpcardio.org/en/2024-05-11_ticagrelor-alone-versus-ticagrelor-plus-aspirin-from-month-1-to-month-12-after-percutaneous-coronary-intervention-in-patients-with-acute-coronary-synd/
https://gpcardio.org/en/2024-05-16_andexanet-for-factor-xa-inhibitor-associated-acute-intracerebral-hemorrhage/
https://gpcardio.org/en/2024-05-16_olezarsen-acute-pancreatitis-and-familial-chylomicronemia-syndrome/
https://gpcardio.org/en/2024-05-16_olezarsen-for-hypertriglyceridemia-in-patients-at-high-cardiovascular-risk/
https://gpcardio.org/en/2024-05-30_intensive-ambulance-delivered-blood-pressure-reduction-in-hyperacute-stroke/
https://gpcardio.org/en/2024-06-01_pulmonary-arterial-hypertension-treatment/
https://gpcardio.org/en/2024-06-04_enhancing-cvd-risk-assessment-integrating-genetic-risk-for-improved-prediction/
https://gpcardio.org/en/2024-06-04_sodium-glucose-cotransporter-2-inhibitors-and-major-adverse-cardiovascular-outcomes/
https://gpcardio.org/en/2024-06-06_self-expanding-or-balloon-expandable-tavr-in-patients-with-a-small-aortic-annulus/
https://gpcardio.org/en/2024-06-14_invasive-vs-conservative-management-of-older-patients-with-non-st-elevation-acute-coronary-syndrome/
https://gpcardio.org/en/2024-06-25_revisiting-race-and-the-benefit-of-ras-blockade-in-heart-failure/
https://gpcardio.org/en/2024-07-01_plozasiran-aro-apoc3-for-severe-hypertriglyceridemia/
https://gpcardio.org/en/2024-07-11_effects-of-semaglutide-on-chronic-kidney-disease-in-patients-with-type-2-diabetes/
https://gpcardio.org/en/2024-07-13_long-term-colchicine-for-the-prevention-of-vascular-recurrent-events-in-non-cardioembolic-stroke-convince/
https://gpcardio.org/en/2024-07-20_lowering-systolic-blood-pressure-to-less-than-120-mm-hg-versus-less-than-140-mm-hg-in-patients-with-high-cardiovascular-risk-with-and-without-diabetes/
https://gpcardio.org/en/2024-08-24_semaglutide-and-cardiovascular-outcomes-in-patients-with-obesity-and-prevalent-heart-failure/
https://gpcardio.org/en/2024-09-01_ticagrelor-monotherapy-for-acute-coronary-syndrome/
https://gpcardio.org/en/2024-09-04_global-insights-from-the-interaspire-study-mapping-lipoprotein-a-prevalence-in-coronary-heart-disease-across-six-who-regions/
https://gpcardio.org/en/2024-09-07_semaglutide-versus-placebo-in-patients-with-heart-failure-and-mildly-reduced-or-preserved-ejection-fraction/
https://gpcardio.org/en/2024-09-12_plozasiran-an-rna-interference-agent-targeting-apoc3-for-mixed-hyperlipidemia/
https://gpcardio.org/en/2024-09-12_zodasiran-an-rnai-therapeutic-targeting-angptl3-for-mixed-hyperlipidemia/
https://gpcardio.org/en/2024-09-14_temporary-mechanical-circulatory-support-in-infarct-related-cardiogenic-shock/
https://gpcardio.org/en/2024-09-21_mineralocorticoid-receptor-antagonists-in-heart-failure/
https://gpcardio.org/en/2024-09-24_2024-acc-expert-consensus-decision-pathway-on-clinical-assessment-management-and-trajectory-of-patients-hospitalized-with-heart-failure-focused-update/
https://gpcardio.org/en/2024-09-29_2024-esc-guidelines-for-the-management-of-atrial-fibrillation-developed-in-collaboration-with-the-european-association-for-cardio-thoracic-surgery-eac/
https://gpcardio.org/en/2024-10-07_2024-esc-guidelines-for-the-management-of-elevated-blood-pressure-and-hypertension/
https://gpcardio.org/en/2024-10-07_semaglutide-and-blood-pressure/
https://gpcardio.org/en/2024-10-10_beta-blocker-interruption-or-continuation-after-myocardial-infarction/
https://gpcardio.org/en/2024-10-22_effects-of-semaglutide-on-heart-failure-outcomes-in-diabetes-and-chronic-kidney-disease-in-the-flow-trial/
https://gpcardio.org/en/2024-10-24_finerenone-in-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction/
https://gpcardio.org/en/2024-10-29_adjudication-of-hospitalizations-and-deaths-in-the-ironman-trial-of-intravenous-iron-for-heart-failure/
https://gpcardio.org/en/2024-11-05_complete-versus-culprit-only-revascularization-in-older-patients-with-st-segment-elevation-myocardial-infarction/
https://gpcardio.org/en/2024-11-07_invasive-treatment-strategy-for-older-patients-with-myocardial-infarction/
https://gpcardio.org/en/2024-11-09_quantitative-flow-ratio-versus-fractional-flow-reserve-for-coronary-revascularisation-guidance-favor-iii-europe/
https://gpcardio.org/en/2024-11-14_transcatheter-repair-versus-mitral-valve-surgery-for-secondary-mitral-regurgitation/
https://gpcardio.org/en/2024-11-14_transcatheter-valve-repair-in-heart-failure-with-moderate-to-severe-mitral-regurgitation/
https://gpcardio.org/en/2024-11-19_effect-of-screening-for-undiagnosed-atrial-fibrillation-on-stroke-prevention/
https://gpcardio.org/en/2024-11-26_cardiovascular-kidney-and-safety-outcomes-with-glp-1-receptor-agonists-alone-and-in-combination-with-sglt2-inhibitors-in-type-2-diabetes/
https://gpcardio.org/en/2024-12-12_pci-in-patients-undergoing-transcatheter-aortic-valve-implantation/
https://gpcardio.org/en/2024-12-14_the-vital-role-of-primary-care-in-advancing-cardiovascular-health/
https://gpcardio.org/en/2025-01-02_asundexian-versus-apixaban-in-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2025-01-07_efficacy-and-safety-of-finerenone-across-the-ejection-fraction-spectrum-in-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction/
https://gpcardio.org/en/2025-01-09_plozasiran-for-managing-persistent-chylomicronemia-and-pancreatitis-risk/
https://gpcardio.org/en/2025-01-09_transcatheter-valve-replacement-in-severe-tricuspid-regurgitation/
https://gpcardio.org/en/2025-01-14_transcatheter-edge-to-edge-repair-for-severe-isolated-tricuspid-regurgitation/
https://gpcardio.org/en/2025-01-21_early-intervention-in-patients-with-asymptomatic-severe-aortic-stenosis-and-myocardial-fibrosis/
https://gpcardio.org/en/2025-01-21_oral-muvalaplin-for-lowering-of-lipoprotein-a/
https://gpcardio.org/en/2025-01-23_abelacimab-versus-rivaroxaban-in-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2025-01-25_coronary-ct-angiography-guided-management-of-patients-with-stable-chest-pain/
https://gpcardio.org/en/2025-01-30_continuation-versus-interruption-of-oral-anticoagulation-during-tavi/
https://gpcardio.org/en/2025-01-30_tirzepatide-for-heart-failure-with-preserved-ejection-fraction-and-obesity/
https://gpcardio.org/en/2025-02-13_colchicine-in-acute-myocardial-infarction/
https://gpcardio.org/en/2025-02-13_routine-spironolactone-in-acute-myocardial-infarction/
https://gpcardio.org/en/2025-02-20_catheter-ablation-or-antiarrhythmic-drugs-for-ventricular-tachycardia/
https://gpcardio.org/en/2025-03-11_transcatheter-aortic-valve-replacement-in-patients-with-systolic-heart-failure-and-moderate-aortic-stenosis/
https://gpcardio.org/en/2025-03-15_study-on-cardiovascular-risk-factors-and-primary-care-utilization-in-spain/
https://gpcardio.org/en/2025-03-16_primary-prevention-of-atherosclerotic-cardiovascular-disease-ascvd-in-primary-care-a-systematic-review-of-guidelines/
https://gpcardio.org/en/2025-03-17_sex-differences-and-trends-in-cardiovascular-risk-management-insights-from-a-long-term-primary-care-study/
https://gpcardio.org/en/2025-03-25_age-and-sex-differences-in-efficacy-of-treatments-for-type-2-diabetes/
https://gpcardio.org/en/2025-03-25_anticoagulation-and-antiplatelet-therapy-for-atrial-fibrillation-and-stable-coronary-disease/
https://gpcardio.org/en/2025-03-25_antithrombotic-therapy-to-minimize-total-events-after-acs-or-pci-in-atrial-fibrillation/
https://gpcardio.org/en/2025-03-27_intensive-blood-pressure-control-in-patients-with-type-2-diabetes/
https://gpcardio.org/en/2025-03-28_flecainide-acetate-inhalation-solution-for-cardioversion-of-recent-onset-symptomatic-atrial-fibrillation/
https://gpcardio.org/en/2025-04-01_2025-acc-aha-guideline-for-the-management-of-patients-with-acute-coronary-syndromes/
https://gpcardio.org/en/2025-04-01_efficacy-and-safety-of-aldosterone-synthase-inhibitors-for-hypertension/
https://gpcardio.org/en/2025-04-01_meta-analysis-of-sotagliflozin-a-dual-sodium-glucose-cotransporter-1-2-inhibitor-for-heart-failure-in-type-2-diabetes/
https://gpcardio.org/en/2025-04-03_left-atrial-appendage-closure-after-ablation-for-atrial-fibrillation/
https://gpcardio.org/en/2025-04-07_empagliflozin-in-resistant-hypertension-and-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2025-04-07_sodium-glucose-co-transporter-2-inhibitors-and-new-onset-diabetes-in-cardiovascular-or-kidney-disease/
https://gpcardio.org/en/2025-04-10_dapagliflozin-in-patients-undergoing-transcatheter-aortic-valve-implantation/
https://gpcardio.org/en/2025-04-10_introducing-gpcardio-bridging-the-gap-in-cardiovascular-care/
https://gpcardio.org/en/2025-04-17_pulsed-field-or-cryoballoon-ablation-for-paroxysmal-atrial-fibrillation/
https://gpcardio.org/en/2025-05-03_semaglutide-and-walking-capacity-in-people-with-symptomatic-peripheral-artery-disease-and-type-2-diabetes-stride/
https://gpcardio.org/en/2025-05-08_lorundrostat-efficacy-and-safety-in-patients-with-uncontrolled-hypertension/
https://gpcardio.org/en/2025-05-13_effect-of-empagliflozin-on-the-mechanisms-driving-erythropoiesis-and-iron-mobilization-in-patients-with-heart-failure/
https://gpcardio.org/en/2025-05-13_interplay-of-chronic-kidney-disease-and-the-effects-of-tirzepatide-in-patients-with-heart-failure-preserved-ejection-fraction-and-obesity/
https://gpcardio.org/en/2025-05-17_fixed-dose-combination-of-obicetrapib-and-ezetimibe-for-ldl-cholesterol-reduction-tandem/
https://gpcardio.org/en/2025-05-29_oral-semaglutide-and-cardiovascular-outcomes-in-high-risk-type-2-diabetes/
https://gpcardio.org/en/2025-06-01_ffr-guided-percutaneous-coronary-intervention-vs-coronary-artery-bypass-grafting-in-patients-with-diabetes/
https://gpcardio.org/en/2025-06-01_novel-controlled-metabolic-accelerator-for-obesity-related-hfpef/
https://gpcardio.org/en/2025-06-01_randomized-trial-to-assess-worsening-renal-function-by-adding-dapagliflozin-for-acute-decompensated-heart-failure/
https://gpcardio.org/en/2025-06-03_an-oral-pcsk9-inhibitor-for-treatment-of-hypercholesterolemia/
https://gpcardio.org/en/2025-06-10_2025-acc-aha-guideline-for-the-management-of-patients-with-acute-coronary-syndromes/
https://gpcardio.org/en/2025-06-10_intravenous-ferric-carboxymaltose-in-heart-failure-with-iron-deficiency/
https://gpcardio.org/en/2025-06-10_oral-semaglutide-and-cardiovascular-outcomes-in-people-with-type-2-diabetes-according-to-sglt2i-use/
https://gpcardio.org/en/2025-06-13_the-impact-of-frailty-on-the-effectiveness-of-intensive-blood-pressure-control-for-patients-with-type-2-diabetes/
https://gpcardio.org/en/2025-06-17_antihypertensive-medication-timing-and-cardiovascular-events-and-death/
https://gpcardio.org/en/2025-06-17_long-acting-factor-xi-inhibition-and-periprocedural-bleeding/
https://gpcardio.org/en/2025-06-17_spironolactone-vs-amiloride-for-resistant-hypertension/
https://gpcardio.org/en/2025-07-01_add-on-treatment-with-zilebesiran-for-inadequately-controlled-hypertension/
https://gpcardio.org/en/2025-07-01_gpcardio-epccs-joins-each-in-european-alliance-for-cardiovascular-health/
https://gpcardio.org/en/2025-07-01_near-universal-prevalence-of-central-adiposity-in-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2025-07-03_safety-and-efficacy-of-obicetrapib-in-patients-at-high-cardiovascular-risk/
https://gpcardio.org/en/2025-07-05_collaboration-on-the-optimal-timing-of-anticoagulation-after-ischaemic-stroke-and-atrial-fibrillation/
https://gpcardio.org/en/2025-07-07_colchicine-for-secondary-prevention-of-vascular-events/
https://gpcardio.org/en/2025-07-07_long-term-trials-of-colchicine-for-secondary-prevention-of-vascular-events/
https://gpcardio.org/en/2025-07-08_catheter-ablation-vs-lifestyle-modification-with-antiarrhythmic-drugs-to-treat-atrial-fibrillation/
https://gpcardio.org/en/2025-07-10_gpcardio-and-acc-s-ncd-academy-join-forces-to-strengthen-primary-care-in-cardiovascular-disease-prevention/
https://gpcardio.org/en/2025-07-12_amycretin-a-novel-unimolecular-glp-1-and-amylin-receptor-agonist-administered-subcutaneously/
https://gpcardio.org/en/2025-07-12_safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-the-first-in-class-glp-1-and-amylin-receptor-agonist-amycretin/
https://gpcardio.org/en/2025-07-15_10-year-outcome-of-complete-or-infarct-artery-only-revascularization-in-stemi-with-multivessel-disease/
https://gpcardio.org/en/2025-07-22_cooperative-pfa/
https://gpcardio.org/en/2025-07-28_long-term-benefits-of-atorvastatin-on-the-incidence-of-cardiovascular-events/
https://gpcardio.org/en/2025-07-29_cvd-primary-care-the-need-for-epccs-practice-guidance/
https://gpcardio.org/en/2025-07-29_impact-of-body-mass-index-central-adiposity-and-weight-loss-on-the-benefits-of-tirzepatide-in-hfpef/
https://gpcardio.org/en/2025-08-05_abelacimab-versus-rivaroxaban-in-patients-with-atrial-fibrillation-on-antiplatelet-therapy/
https://gpcardio.org/en/2025-08-05_lorundrostat-in-participants-with-uncontrolled-hypertension-and-treatment-resistant-hypertension/
https://gpcardio.org/en/2025-08-05_sodium-glucose-cotransporter-2-inhibitor-with-and-without-an-aldosterone-antagonist-for-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2025-08-12_outcomes-in-older-patients-after-switching-to-a-newer-anticoagulant-or-remaining-on-warfarin/
https://gpcardio.org/en/2025-08-14_coadministered-cagrilintide-and-semaglutide-in-adults-with-overweight-or-obesity/
https://gpcardio.org/en/2025-08-21_preventive-percutaneous-coronary-intervention-for-non-flow-limiting-vulnerable-atherosclerotic-coronary-plaques-in-diabetes/
https://gpcardio.org/en/2025-08-30_blood-pressure-lowering-efficacy-of-antihypertensive-drugs-and-their-combinations/
https://gpcardio.org/en/2025-09-01_conduction-system-pacing-vs-biventricular-pacing-for-cardiac-resynchronization/
https://gpcardio.org/en/2025-09-01_cost-effectiveness-of-apixaban-vs-aspirin-for-the-reduction-of-thrombo-embolism-in-high-risk-patients-with-device-detected-atrial-fibrillation/
https://gpcardio.org/en/2025-09-01_diabetes-and-obesity-and-treatment-effect-of-early-rhythm-control-vs-usual-care-in-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2025-09-02_optimal-medical-care-and-coronary-flow-capacity-guided-myocardial-revascularization-vs-usual-care-for-chronic-coronary-artery-disease/
https://gpcardio.org/en/2025-09-02_remote-atrial-fibrillation-screening-in-primary-care-using-an-ecg-patch-demonstrates-modest-benefits/
https://gpcardio.org/en/2025-09-05_blood-pressure-reductions-with-baxdrostat-in-patients-with-uncontrolled-or-resistant-hypertension/
https://gpcardio.org/en/2025-09-09_influence-of-type-2-diabetes-on-the-effects-of-tirzepatide-in-patients-with-heart-failure-and-a-preserved-ejection-fraction-with-obesity/
https://gpcardio.org/en/2025-09-11_multidomain-rehabilitation-for-older-patients-with-myocardial-infarction/
https://gpcardio.org/en/2025-09-11_new-guidance-recommends-a-new-approach-to-assess-cardiovascular-risk-and-reach-treatment-goals-for-lipid-levels/
https://gpcardio.org/en/2025-09-13_β-blockers-after-myocardial-infarction-with-mildly-reduced-ejection-fraction/
https://gpcardio.org/en/2025-09-16_2025-aha-acc-guideline-for-the-prevention-detection-evaluation-and-management-of-high-blood-pressure-in-adults/
https://gpcardio.org/en/2025-09-16_tackling-the-enduring-cardiovascular-impact-of-covid-19-new-guidance-for-primary-care/
https://gpcardio.org/en/2025-09-18_orforglipron-an-oral-small-molecule-glp-1-receptor-agonist-in-early-type-2-diabetes/
https://gpcardio.org/en/2025-09-20_effect-of-evolocumab-on-saphenous-vein-graft-patency-after-coronary-artery-bypass-surgery-newton-cabg-cardiolink-5/
https://gpcardio.org/en/2025-09-21_introduction-and-the-impact-of-cmr-on-patients-and-health-systems/
https://gpcardio.org/en/2025-09-24_key-changes-in-clinical-guidance-for-blood-pressure-and-lipid-management/
https://gpcardio.org/en/2025-09-25_digitoxin-in-patients-with-heart-failure-and-reduced-ejection-fraction/
https://gpcardio.org/en/2025-09-28_why-it-s-important-to-recognise-manage-chronic-kidney-disease-ckd/
https://gpcardio.org/en/2025-10-01_2025-aha-acc-guideline-for-the-prevention-detection-evaluation-and-management-of-high-blood-pressure-in-adults/
https://gpcardio.org/en/2025-10-01_no-evidence-supports-vitamins-or-supplements-for-lowering-ldl-cholesterol-and-reducing-cardiovascular-risk/
https://gpcardio.org/en/2025-10-01_pulmonary-congestion-relief-by-adding-dapagliflozin-to-intravenous-loop-diuretic-in-acute-heart-failure-patients/
https://gpcardio.org/en/2025-10-07_impact-of-obicetrapib-on-major-adverse-cardiovascular-events-in-high-risk-patients/
https://gpcardio.org/en/2025-10-07_left-atrial-appendage-occlusion-in-patients-with-end-stage-renal-disease/
https://gpcardio.org/en/2025-10-07_the-relationship-between-obesity-and-chronic-kidney-disease/
https://gpcardio.org/en/2025-10-09_efficacy-and-safety-of-baxdrostat-in-uncontrolled-and-resistant-hypertension/
https://gpcardio.org/en/2025-10-14_heparin-administration-at-first-medical-contact-vs-immediately-before-primary-percutaneous-coronary-intervention/
https://gpcardio.org/en/2025-10-14_long-term-anticoagulation-discontinuation-after-catheter-ablation-for-atrial-fibrillation/
https://gpcardio.org/en/2025-10-23_aspirin-in-patients-with-chronic-coronary-syndrome-receiving-oral-anticoagulation/
https://gpcardio.org/en/2025-10-27_bridging-heart-and-stroke-awareness-stronger-together/
https://gpcardio.org/en/2025-10-27_transcatheter-or-surgical-aortic-valve-replacement-in-low-risk-patients-at-7-years/
https://gpcardio.org/en/2025-10-28_effect-of-intensive-blood-pressure-control-on-stroke/
https://gpcardio.org/en/2025-10-28_immediate-or-deferred-nonculprit-lesion-pci-in-myocardial-infarction/
https://gpcardio.org/en/2025-10-28_intensive-blood-pressure-control-in-older-patients-with-hypertension/
https://gpcardio.org/en/2025-11-01_safety-of-factor-xi-inhibition-with-abelacimab-in-atrial-fibrillation-by-kidney-function/
https://gpcardio.org/en/2025-11-04_2025-aha-acc-guideline-for-the-prevention-detection-evaluation-and-management-of-high-blood-pressure-in-adults/
https://gpcardio.org/en/2025-11-06_orforglipron-an-oral-small-molecule-glp-1-receptor-agonist-for-obesity-treatment/
https://gpcardio.org/en/2025-11-09_pcsk9-inhibitor-prevents-first-heart-attack-or-stroke-in-high-risk-patients/
https://gpcardio.org/en/2025-11-10_high-dose-vs-standard-dose-influenza-vaccine-and-cardiovascular-outcomes-in-older-adults/
https://gpcardio.org/en/2025-11-11_decaf-a-cup-of-coffee-a-day-could-keep-atrial-fibrillation-from-coming-back/
https://gpcardio.org/en/2025-11-13_beta-blockers-after-myocardial-infarction-in-patients-without-heart-failure/
https://gpcardio.org/en/2025-11-13_beta-blockers-after-myocardial-infarction-without-reduced-ejection-fraction/
https://gpcardio.org/en/2025-11-18_2025-acc-scientific-statement-on-the-management-of-obesity-in-adults-with-heart-failure/
https://gpcardio.org/en/2025-11-18_cardiovascular-effects-and-tolerability-of-glp-1-receptor-agonists/
https://gpcardio.org/en/2025-11-18_dapagliflozin-in-patients-hospitalized-for-heart-failure/
https://gpcardio.org/en/2025-11-21_epccs-council-launches-gpcardio-as-a-commitment-to-support-primary-care/
https://gpcardio.org/en/2025-11-25_biomarker-based-abc-af-risk-scores-for-personalized-treatment-to-reduce-stroke-or-death-in-atrial-fibrillation/
https://gpcardio.org/en/2025-12-01_aggressive-risk-factor-reduction-study-for-atrial-fibrillation-implications-for-ablation-outcomes/
https://gpcardio.org/en/2025-12-01_major-bleeding-with-apixaban-vs-aspirin/
https://gpcardio.org/en/2025-12-13_complete-versus-culprit-lesion-only-revascularisation-for-acute-myocardial-infarction-complete-revascularisation-trialists-collaboration/
https://gpcardio.org/en/2025-12-16_long-term-effect-of-icds-in-nonischemic-heart-failure-with-reduced-ejection-fraction/
https://gpcardio.org/en/2025-12-16_pharmacologic-treatment-of-heart-failure-with-reduced-ejection-fraction/
https://gpcardio.org/en/2025-12-18_2025-acc-aha-guideline-for-the-management-of-adults-with-congenital-heart-disease/
https://gpcardio.org/en/2025-12-18_cardiovascular-outcomes-with-tirzepatide-versus-dulaglutide-in-type-2-diabetes/
https://gpcardio.org/en/2025-12-18_improve-dice-a-2-part-open-label-phase-2a-trial-evaluating-the-safety-and-effectiveness-of-ninerafaxstat-in-patients-with-cardiometabolic-syndromes/
https://gpcardio.org/en/2025-12-19_eu-launches-ambitious-safe-hearts-plan-a-new-roadmap-in-cardiovascular-health/
https://gpcardio.org/en/2025-12-20_orforglipron-an-oral-small-molecule-glp-1-receptor-agonist-for-the-treatment-of-obesity-in-people-with-type-2-diabetes-attain-2/
https://gpcardio.org/en/2025-12-23_short-term-anticoagulation-versus-dual-antiplatelet-therapy-for-preventing-device-thrombosis-following-left-atrial-appendage-closure/
https://gpcardio.org/en/2026-01-06_dash-patterned-groceries-and-effects-on-blood-pressure/
https://gpcardio.org/en/2026-01-06_global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity-issued-by-who/
https://gpcardio.org/en/2026-01-07_cxcr6-t-cells-drive-immune-checkpoint-inhibitor-myocarditis/
https://gpcardio.org/en/2026-01-10_nicotine-and-the-cardiovascular-system-key-insights-for-primary-care/
https://gpcardio.org/en/2026-01-12_efficacy-and-safety-of-treatment-with-low-doses-of-spironolactone-in-patients-with-primary-aldosteronism/
https://gpcardio.org/en/2026-01-13_efficacy-and-safety-of-oral-pcsk9-inhibitor-enlicitide-in-adults-with-heterozygous-familial-hypercholesterolemia/
https://gpcardio.org/en/2026-01-14_glucagon-like-receptor-agonists-and-next-generation-incretin-based-medications/
https://gpcardio.org/en/2026-01-15_socioeconomic-and-structural-barriers-to-addressing-obesity-in-communities/
https://gpcardio.org/en/2026-01-19_stroke-identified-as-the-second-leading-cause-of-death-from-cardiovascular-disease-and-a-major-contributor-of-acquired-long-term-disability/
https://gpcardio.org/en/2026-01-20_environmental-stressors-and-cardiovascular-health/
https://gpcardio.org/en/2026-01-20_sglt2-inhibitors-and-kidney-outcomes-by-glomerular-filtration-rate-and-albuminuria/
https://gpcardio.org/en/2026-01-20_triple-versus-dual-lipid-lowering-therapy-in-acute-coronary-syndrome/
https://gpcardio.org/en/2026-01-21_2026-heart-disease-and-stroke-statistics/
https://gpcardio.org/en/2026-01-22_antithrombotic-therapy-after-successful-catheter-ablation-for-atrial-fibrillation/
https://gpcardio.org/en/2026-01-22_drug-stewardship-for-ras-inhibitors-and-sglt2-inhibitors-in-chronic-kidney-disease/
https://gpcardio.org/en/2026-01-27_colchicine-in-acute-coronary-syndromes/
https://gpcardio.org/en/2026-01-27_potent-p2y12-inhibitor-monotherapy-vs-dapt-after-pci-in-patients-with-and-without-stemi/
https://gpcardio.org/en/2026-01-28_kdigo-2026-clinical-practice-guideline-for-anemia-in-chronic-kidney-disease-ckd/
https://gpcardio.org/en/2026-01-29_olezarsen-for-managing-severe-hypertriglyceridemia-and-pancreatitis-risk/
https://gpcardio.org/en/2026-01-29_wearable-derived-training-load-and-coronary-atherosclerosis-in-middle-aged-and-older-athletes-and-physically-active-controls/
https://gpcardio.org/en/2026-01-30_systemic-embolic-events-in-atrial-fibrillation/
https://gpcardio.org/en/2026-02-01_cagrisema-reduces-blood-pressure-in-adults-with-overweight-or-obesity/
https://gpcardio.org/en/2026-02-01_cardiovascular-kidney-effects-of-dapagliflozin-in-patients-at-cardiovascular-risk-with-or-without-type-2-diabetes/
https://gpcardio.org/en/2026-02-01_outcomes-after-switching-cardiac-troponin-assays-in-acs/
https://gpcardio.org/en/2026-02-01_semaglutide-and-hospitalizations-in-patients-with-obesity-and-established-cardiovascular-disease/
https://gpcardio.org/en/2026-02-01_β-blockers-after-myocardial-infarction-in-patients-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-02-02_sglt2-inhibitor-use-and-cardiorenal-outcomes-in-type-2-diabetes-with-liver-cirrhosis/
https://gpcardio.org/en/2026-02-03_contemporary-management-of-atrial-fibrillation-in-patients-with-cancer-the-2025-european-heart-rhythm-association-survey/
https://gpcardio.org/en/2026-02-03_dapagliflozin-to-reduce-early-recurrence-after-catheter-ablation-for-atrial-fibrillation/
https://gpcardio.org/en/2026-02-03_physical-activity-and-risk-of-adverse-events-in-atrial-fibrillation/
https://gpcardio.org/en/2026-02-03_semaglutide-as-adjunctive-therapy-to-catheter-ablation-in-obesity-related-paroxysmal-atrial-fibrillation/
https://gpcardio.org/en/2026-02-03_semaglutide-vs-tirzepatide-in-patients-with-obesity-and-hfpef/
https://gpcardio.org/en/2026-02-04_ai-digital-stethoscopes-outperform-traditional-screening-for-significant-vhd/
https://gpcardio.org/en/2026-02-05_efimosfermin-alfa-bos-580-once-per-month-in-people-with-metabolic-dysfunction-associated-steatohepatitis-with-f2-or-f3-fibrosis/
https://gpcardio.org/en/2026-02-05_intravenous-tenecteplase-for-acute-ischaemic-stroke-within-24-h-due-to-basilar-artery-occlusion/
https://gpcardio.org/en/2026-02-05_tenecteplase-versus-standard-medical-treatment-for-basilar-artery-occlusion-within-24-h-trace-5/
https://gpcardio.org/en/2026-02-06_glucagon-like-peptide-receptor-agonists-and-kidney-outcomes-in-the-era-of-personalized-medicine/
https://gpcardio.org/en/2026-02-06_insulin-resistance-compromises-the-pentose-phosphate-pathway-and-impairs-left-ventricular-assist-device-mediated-myocardial-recovery-in-obese-patients/
https://gpcardio.org/en/2026-02-06_talking-to-patients-about-statins-why-most-reported-symptoms-aren-t-causal/
https://gpcardio.org/en/2026-02-06_the-aldehyde-dehydrogenase-2-rs671-variant-enhances-platelet-activation-and-arterial-thrombosis/
https://gpcardio.org/en/2026-02-09_coronary-atherosclerosis-in-patients-with-cancer-and-survivors/
https://gpcardio.org/en/2026-02-10_clonal-hematopoiesis-and-its-cardiovascular-implications/
https://gpcardio.org/en/2026-02-10_new-drug-therapies-for-hypertension/
https://gpcardio.org/en/2026-02-10_renal-and-urothelial-cancer-risks-with-sglt2-inhibitors-vs-glp-1-receptor-agonists-in-type-2-diabetes/
https://gpcardio.org/en/2026-02-10_spontaneous-myocardial-infarction-after-left-main-revascularization/
https://gpcardio.org/en/2026-02-10_transthyretin-cardiac-amyloidosis-evaluation-and-management/
https://gpcardio.org/en/2026-02-11_aspirin-dosing-after-acute-coronary-syndrome-with-suspected-aspirin-resistance/
https://gpcardio.org/en/2026-02-11_criteria-to-assess-the-predictive-and-clinical-utility-of-novel-models-biomarkers-and-tools-for-risk-of-cardiovascular-disease/
https://gpcardio.org/en/2026-02-11_improving-outcomes-of-atrial-fibrillation-ablation-by-integrated-personalized-lifestyle-interventions/
https://gpcardio.org/en/2026-02-11_vericiguat-and-mortality-in-heart-failure-and-reduced-ejection-fraction/
https://gpcardio.org/en/2026-02-12_prospective-associations-of-obesity-and-obesity-severity-with-9-cardiovascular-outcomes/
https://gpcardio.org/en/2026-02-13_use-of-kidney-preserving-medications-in-breastfeeding/
https://gpcardio.org/en/2026-02-16_early-versus-late-anticoagulation-treatment-after-acute-ischemic-stroke-with-atrial-fibrillation/
https://gpcardio.org/en/2026-02-16_novel-plasma-proteomic-markers-and-risk-of-venous-thromboembolism/
https://gpcardio.org/en/2026-02-17_albuminuria-or-proteinuria-in-glomerular-disease-and-ckd-which-one-to-use/
https://gpcardio.org/en/2026-02-18_beta-blockers-after-myocardial-infarction/
https://gpcardio.org/en/2026-02-18_gene-therapy-for-nephropathic-cystinosis/
https://gpcardio.org/en/2026-02-19_2026-aha-acc-guideline-for-the-evaluation-and-management-of-acute-pulmonary-embolism-in-adults/
https://gpcardio.org/en/2026-02-19_cardiovascular-kidney-metabolic-interplay-in-patients-with-atrial-fibrillation-receiving-direct-oral-anticoagulants/
https://gpcardio.org/en/2026-02-19_conduction-disturbances-after-transcatheter-aortic-valve-implantation/
https://gpcardio.org/en/2026-02-19_secondary-prevention-after-ischemic-stroke/
https://gpcardio.org/en/2026-02-19_transcatheter-or-surgical-aortic-valve-replacement-in-low-risk-patients-at-7-years/
https://gpcardio.org/en/2026-02-21_pelacarsen-and-lipoprotein-a-apheresis-in-secondary-prevention/
https://gpcardio.org/en/2026-02-22_cost-effectiveness-of-sodium-glucose-cotransporter-2-inhibitors-and-glucagon-like-peptide-1-receptor-agonists-for-patients-with-high-cardiovascular-ri/
https://gpcardio.org/en/2026-02-23_accelerometry-defined-physical-activity-and-quality-of-life-in-hypertrophic-cardiomyopathy/
https://gpcardio.org/en/2026-02-23_diabetes-increases-the-risk-of-heart-failure-in-myocarditis/
https://gpcardio.org/en/2026-02-23_effect-of-semaglutide-on-covid-19-and-other-infections/
https://gpcardio.org/en/2026-02-23_immunoadsorption-in-dilated-cardiomyopathy/
https://gpcardio.org/en/2026-02-23_mitigating-risk-of-kidney-dysfunction-after-heart-transplantation-and-therapeutic-approaches/
https://gpcardio.org/en/2026-02-23_primary-care-adherence-to-heart-failure-guidelines-in-post-discharge-evaluation-routine-management-pathfinder/
https://gpcardio.org/en/2026-02-23_the-year-in-cardiovascular-medicine-2025/
https://gpcardio.org/en/2026-02-24_malnutrition-and-cachexia-in-inpatients-with-acute-cardiac-conditions/
https://gpcardio.org/en/2026-02-24_risk-of-heart-failure-hospitalization-for-glp-1-receptor-agonists-versus-dpp-4-inhibitors-or-sglt-2-inhibitors-in-patients-with-type-2-diabetes/
https://gpcardio.org/en/2026-02-24_systemic-embolic-events-in-atrial-fibrillation/
https://gpcardio.org/en/2026-02-25_combined-associations-of-glp-1-receptor-agonists-and-a-healthy-lifestyle-with-cardiovascular-outcomes-among-individuals-with-type-2-diabetes/
https://gpcardio.org/en/2026-02-25_forecasting-the-burden-of-cardiovascular-disease-and-stroke-in-women-in-the-united-states-through-2050/
https://gpcardio.org/en/2026-02-25_low-dose-rivaroxaban-to-prevent-left-ventricular-thrombosis-after-anterior-myocardial-infarction/
https://gpcardio.org/en/2026-02-25_outcomes-of-heart-failure-with-reduced-mildly-reduced-or-preserved-ejection-fraction/
https://gpcardio.org/en/2026-02-26_intensive-bp-control-and-cognitive-function/
https://gpcardio.org/en/2026-02-27_additive-cardiorenal-benefits-of-finerenone-and-sglt2-inhibitor-combination-therapy-in-diabetic-ckd/
https://gpcardio.org/en/2026-02-27_carotid-plaque-macrophage-burden-and-inflammatory-lipid-associated-macrophage-markers-predict-secondary-major-adverse-cardiovascular-events-after-enda/
https://gpcardio.org/en/2026-02-27_sglt2-inhibition-in-patients-with-type-2-diabetes-and-ckd-experiencing-a-deterioration-in-estimated-glomerular-filtration-rate-to-20ml-min-1-73m/
https://gpcardio.org/en/2026-02-27_switching-from-warfarin-to-direct-oral-anticoagulants-in-frail-elderly-asian-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-02-28_heart-failure-in-the-elderly/
https://gpcardio.org/en/2026-03-01_2026-acute-pulmonary-embolism-guideline-at-a-glance/
https://gpcardio.org/en/2026-03-01_abelacimab-vs-rivaroxaban-in-older-individuals-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-01_cardiac-screening-for-conditions-associated-with-sudden-cardiac-death/
https://gpcardio.org/en/2026-03-01_cardiac-screening-in-the-young/
https://gpcardio.org/en/2026-03-01_comparison-of-the-european-society-of-cardiology-0-1-hour-and-high-sensitivity-troponin-in-the-evaluation-of-patients-with-suspected-acute-coronary-sy/
https://gpcardio.org/en/2026-03-01_effect-of-baduanjin-on-blood-pressure-among-individuals-with-high-normal-blood-pressure/
https://gpcardio.org/en/2026-03-01_high-dose-influenza-vaccination-in-atherosclerotic-cardiovascular-disease/
https://gpcardio.org/en/2026-03-01_impact-of-early-delayed-or-interrupted-treatment-in-children-with-familial-hypercholesterolemia/
https://gpcardio.org/en/2026-03-01_journal-club/
https://gpcardio.org/en/2026-03-01_six-year-outcomes-after-transcatheter-vs-surgical-aortic-valve-replacement-in-low-risk-patients-with-aortic-stenosis/
https://gpcardio.org/en/2026-03-01_some-much-needed-confidence-to-combat-the-risk-treatment-paradox-in-chronic-kidney-disease/
https://gpcardio.org/en/2026-03-01_timing-of-cardiovascular-and-kidney-benefits-with-finerenone-in-heart-failure-and-chronic-kidney-disease-with-type-2-diabetes/
https://gpcardio.org/en/2026-03-02_nighttime-road-traffic-noise-stresses-the-heart-and-blood-vessels/
https://gpcardio.org/en/2026-03-04_aspirin-after-pci-in-acute-coronary-syndromes/
https://gpcardio.org/en/2026-03-04_blood-pressure-targets-in-hypertension-management/
https://gpcardio.org/en/2026-03-04_finerenone-for-diabetic-kidney-disease-in-type-1-diabetes-a-fine-answer/
https://gpcardio.org/en/2026-03-04_interplay-of-age-and-sex-with-clinic-and-ambulatory-blood-pressure-and-mortality/
https://gpcardio.org/en/2026-03-05_direct-acting-oral-anticoagulant-or-vitamin-k-antagonist-for-the-frail-elderly-patient-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-05_finerenone-in-type-1-diabetes-and-chronic-kidney-disease/
https://gpcardio.org/en/2026-03-05_oral-pcsk9-inhibitor-enlicitide-lowers-ldl-cholesterol-levels-in-phase-2-trial/
https://gpcardio.org/en/2026-03-05_semaglutide-in-peripheral-artery-disease-and-diabetes-by-baseline-disease-severity-and-age/
https://gpcardio.org/en/2026-03-06_kidney-disease-and-heart-failure/
https://gpcardio.org/en/2026-03-07_atrial-fibrillation/
https://gpcardio.org/en/2026-03-07_effect-of-baxdrostat-on-ambulatory-blood-pressure-in-patients-with-resistant-hypertension-bax24/
https://gpcardio.org/en/2026-03-07_effect-of-baxdrostat-on-ambulatory-blood-pressure-in-patients-with-resistant-hypertension-bax24/
https://gpcardio.org/en/2026-03-09_semaglutide-promotes-bone-marrow-derived-progenitor-cell-flux-towards-an-anti-inflammatory-and-pro-regenerative-profile-in-high-risk-patients/
https://gpcardio.org/en/2026-03-09_targets-and-treatments-to-manage-ldl-c-in-primary-care/
https://gpcardio.org/en/2026-03-10_genetic-screening-for-fh-rationale-and-experience/
https://gpcardio.org/en/2026-03-10_lp-a-time-to-start-measuring-in-primary-care/
https://gpcardio.org/en/2026-03-11_triglycerides-a-risk-marker-or-target-for-cv-risk/
https://gpcardio.org/en/2026-03-12_cardiovascular-metabolic-risk-in-menopause/
https://gpcardio.org/en/2026-03-12_esc-guidance-on-cvd-and-mental-health-in-primary-care/
https://gpcardio.org/en/2026-03-12_off-label-underdosing-of-edoxaban-antithrombotic-therapy-for-patients-with-atrial-fibrillation-and-stable-coronary-artery-disease/
https://gpcardio.org/en/2026-03-13_2026-acc-aha-guideline-on-the-management-of-dyslipidemia/
https://gpcardio.org/en/2026-03-13_heart-failure-in-primary-care-early-recognition-and-initiation-of-gdmt/
https://gpcardio.org/en/2026-03-13_managing-difficult-to-control-hypertension-and-what-s-new/
https://gpcardio.org/en/2026-03-13_the-need-for-gp-engagement-in-the-world-of-advocacy/
https://gpcardio.org/en/2026-03-14_the-pulse-of-primary-care-epccs-summit-2026/
https://gpcardio.org/en/2026-03-16_use-of-coronary-artery-calcium-scoring-in-individuals-with-elevated-lipoprotein-a/
https://gpcardio.org/en/2026-03-20_the-impact-of-epccs-guidance-on-pharmacotherapy-in-ukraine/
https://gpcardio.org/en/2026-03-22_cardiovascular-risk-management-in-poland/
https://gpcardio.org/en/2026-03-22_hypertension-guidelines-update-in-turkey/
https://gpcardio.org/en/2026-03-22_screening-for-cvd-in-greece/
https://gpcardio.org/en/2026-03-23_guideline-directed-medical-therapy-in-ckd-the-crucial-role-for-primary-care/
https://gpcardio.org/en/2026-03-24_managing-ckd-in-primary-care/
https://gpcardio.org/en/2026-03-24_screening-risk-stratification-in-ckd-the-crucial-role-for-primary-care/
https://gpcardio.org/en/2026-03-24_systemic-inflammation-and-recurrence-after-atrial-fibrillation-related-stroke/
https://gpcardio.org/en/2026-03-26_left-atrial-appendage-closure-or-medical-therapy-in-atrial-fibrillation/
https://gpcardio.org/en/2026-03-26_novel-cardiovascular-metabolic-risk-factor-mechanisms-and-therapeutic-opportunities/
https://gpcardio.org/en/2026-03-27_2-year-outcomes-with-the-absorb-bioresorbable-scaffold-for-treatment-of-coronary-artery-disease/
https://gpcardio.org/en/2026-03-27_2015-acc-aha-scai-focused-update-on-primary-percutaneous-coronary-intervention-for-patients-with-st-elevation-myocardial-infarction/
https://gpcardio.org/en/2026-03-27_2015-esc-ers-guidelines-for-the-diagnosis-and-treatment-of-pulmonary-hypertension/
https://gpcardio.org/en/2026-03-27_2015-esc-guidelines-for-the-management-of-acute-coronary-syndromes-in-patients-presenting-without-persistent-st-segment-elevation/
https://gpcardio.org/en/2026-03-27_2016-acc-aha-hfsa-focused-update-on-new-pharmacological-therapy-for-heart-failure/
https://gpcardio.org/en/2026-03-27_2016-esc-eas-guidelines-for-the-management-of-dyslipidaemias/
https://gpcardio.org/en/2026-03-27_2016-esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-failure/
https://gpcardio.org/en/2026-03-27_2016-esc-guidelines-for-the-management-of-atrial-fibrillation-developed-in-collaboration-with-eacts/
https://gpcardio.org/en/2026-03-27_2016-esc-guidelines-for-the-management-of-atrial-fibrillation-developed-in-collaboration-with-eacts/
https://gpcardio.org/en/2026-03-27_2016-european-guidelines-on-cardiovascular-disease-prevention-in-clinical-practice/
https://gpcardio.org/en/2026-03-27_2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection-evaluation-and-management-of-high-blood-pressure-in-adult/
https://gpcardio.org/en/2026-03-27_2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection-evaluation-and-management-of-high-blood-pressure-in-adult/
https://gpcardio.org/en/2026-03-27_2017-acc-aha-hfsa-focused-update-of-the-2013-accf-aha-guideline-for-the-management-of-heart-failure/
https://gpcardio.org/en/2026-03-27_2017-acc-aha-hfsa-focused-update-of-the-2013-accf-aha-guideline-for-the-management-of-heart-failure/
https://gpcardio.org/en/2026-03-27_2017-esc-guidelines-for-the-management-of-acute-myocardial-infarction-in-patients-presenting-with-st-segment-elevation/
https://gpcardio.org/en/2026-03-27_2017-focused-update-of-the-2016-acc-expert-consensus-decision-pathway-on-the-role-of-non-statin-therapies-for-ldl-cholesterol-lowering-in-the-manageme/
https://gpcardio.org/en/2026-03-27_2017-hrs-ehra-ecas-aphrs-solaece-expert-consensus-statement-on-catheter-and-surgical-ablation-of-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_2017-hrs-ehra-ecas-aphrs-solaece-expert-consensus-statement-on-catheter-and-surgical-ablation-of-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_2017-update-of-esc-eas-task-force-on-practical-clinical-guidance-for-proprotein-convertase-subtilisin-kexin-type-9-inhibition-in-patients-with-atheros/
https://gpcardio.org/en/2026-03-27_2018-acc-expert-consensus-decision-pathway-on-novel-therapies-for-cardiovascular-risk-reduction-in-patients-with-type-2-diabetes-and-atherosclerotic-c/
https://gpcardio.org/en/2026-03-27_2020-international-society-of-hypertension-global-hypertension-practice-guidelines/
https://gpcardio.org/en/2026-03-27_2020-update-to-the-2016-acc-aha-clinical-performance-and-quality-measures-for-adults-with-atrial-fibrillation-or-atrial-flutter/
https://gpcardio.org/en/2026-03-27_2024-update-to-the-2020-acc-aha-clinical-performance-and-quality-measures-for-adults-with-heart-failure/
https://gpcardio.org/en/2026-03-27_2025-acc-aha-hrs-isachd-scai-guideline-for-the-management-of-adults-with-congenital-heart-disease/
https://gpcardio.org/en/2026-03-27_3-year-clinical-outcomes-with-everolimus-eluting-bioresorbable-coronary-scaffolds/
https://gpcardio.org/en/2026-03-27_4-year-outcomes-after-left-atrial-appendage-closure-versus-nonwarfarin-oral-anticoagulation-for-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_5-year-outcomes-after-left-atrial-appendage-closure/
https://gpcardio.org/en/2026-03-27_6-month-versus-12-month-or-longer-dual-antiplatelet-therapy-after-percutaneous-coronary-intervention-in-patients-with-acute-coronary-syndrome-smart-da/
https://gpcardio.org/en/2026-03-27_a-cluster-randomized-trial-of-blood-pressure-reduction-in-black-barbershops/
https://gpcardio.org/en/2026-03-27_a-comprehensive-analysis-of-the-effects-of-rivaroxaban-on-stroke-or-transient-ischaemic-attack-in-patients-with-heart-failure-coronary-artery-disease-/
https://gpcardio.org/en/2026-03-27_a-comprehensive-individual-patient-data-meta-analysis-of-the-effects-of-cardiac-contractility-modulation-on-functional-capacity-and-heart-failure-rela/
https://gpcardio.org/en/2026-03-27_a-comprehensive-lifestyle-peer-group-based-intervention-on-cardiovascular-risk-factors/
https://gpcardio.org/en/2026-03-27_a-digital-health-intervention-to-lower-cardiovascular-risk/
https://gpcardio.org/en/2026-03-27_a-fully-magnetically-levitated-circulatory-pump-for-advanced-heart-failure/
https://gpcardio.org/en/2026-03-27_a-highly-durable-rnai-therapeutic-inhibitor-of-pcsk9/
https://gpcardio.org/en/2026-03-27_a-meta-analysis-of-clinical-risk-factors-for-stroke-in-anticoagulant-naive-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_a-meta-analysis-of-continuous-positive-airway-pressure-therapy-in-prevention-of-cardiovascular-events-in-patients-with-obstructive-sleep-apnoea/
https://gpcardio.org/en/2026-03-27_a-multicenter-single-blind-randomized-warfarin-controlled-trial-of-edoxaban-in-patients-with-chronic-thromboembolic-pulmonary-hypertension/
https://gpcardio.org/en/2026-03-27_a-multifaceted-intervention-to-improve-treatment-with-oral-anticoagulants-in-atrial-fibrillation-impact-af/
https://gpcardio.org/en/2026-03-27_a-novel-risk-prediction-score-in-atrial-fibrillation-for-a-net-clinical-outcome-from-the-engage-af-timi-48-randomized-clinical-trial/
https://gpcardio.org/en/2026-03-27_a-prospective-randomized-trial-of-direct-oral-anticoagulant-therapy-with-a-fully-magnetically-levitated-lvad/
https://gpcardio.org/en/2026-03-27_a-randomized-controlled-study-of-finerenone-vs-eplerenone-in-patients-with-worsening-chronic-heart-failure-and-diabetes-mellitus-and-or-chronic-kidney/
https://gpcardio.org/en/2026-03-27_a-randomized-controlled-trial-comparing-apixaban-with-the-vitamin-k-antagonist-phenprocoumon-in-patients-on-chronic-hemodialysis/
https://gpcardio.org/en/2026-03-27_a-randomized-controlled-trial-of-dapagliflozin-on-left-ventricular-hypertrophy-in-people-with-type-two-diabetes/
https://gpcardio.org/en/2026-03-27_a-randomized-controlled-trial-of-metformin-on-left-ventricular-hypertrophy-in-patients-with-coronary-artery-disease-without-diabetes/
https://gpcardio.org/en/2026-03-27_a-randomized-multicentre-trial-to-compare-revascularization-with-optimal-medical-therapy-for-the-treatment-of-chronic-total-coronary-occlusions/
https://gpcardio.org/en/2026-03-27_a-systematic-review-of-clinical-prediction-rules-for-the-diagnosis-of-chronic-heart-failure/
https://gpcardio.org/en/2026-03-27_abdominal-obesity-is-associated-with-an-increased-risk-of-all-cause-mortality-in-patients-with-hfpef/
https://gpcardio.org/en/2026-03-27_ablation-versus-anti-arrhythmic-therapy-for-reducing-all-hospital-episodes-from-recurrent-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_acc-aats-aha-ase-asnc-scai-scct-sts-2016-appropriate-use-criteria-for-coronary-revascularization-in-patients-with-acute-coronary-syndromes/
https://gpcardio.org/en/2026-03-27_achieved-blood-pressure-and-cardiovascular-outcomes-in-high-risk-patients/
https://gpcardio.org/en/2026-03-27_acute-aerobic-exercise-induces-short-term-reductions-in-ambulatory-blood-pressure-in-patients-with-hypertension/
https://gpcardio.org/en/2026-03-27_acute-aortic-dissection-and-intramural-hematoma/
https://gpcardio.org/en/2026-03-27_acute-pleiotropic-effects-of-dapagliflozin-in-type-2-diabetic-patients-with-heart-failure-with-reduced-ejection-fraction/
https://gpcardio.org/en/2026-03-27_adherence-to-cpap-treatment-and-the-risk-of-recurrent-cardiovascular-events/
https://gpcardio.org/en/2026-03-27_adherence-to-single-pill-versus-free-equivalent-combination-therapy-in-hypertension/
https://gpcardio.org/en/2026-03-27_adverse-events-associated-with-unblinded-but-not-with-blinded-statin-therapy-in-the-anglo-scandinavian-cardiac-outcomes-trial-lipid-lowering-arm-ascot/
https://gpcardio.org/en/2026-03-27_aerobic-interval-training-reduces-the-burden-of-atrial-fibrillation-in-the-short-term/
https://gpcardio.org/en/2026-03-27_aerobic-resistance-or-combined-exercise-training-and-cardiovascular-risk-profile-in-overweight-or-obese-adults/
https://gpcardio.org/en/2026-03-27_aficamten-in-obstructive-hypertrophic-cardiomyopathy/
https://gpcardio.org/en/2026-03-27_aflibercept-monotherapy-or-bevacizumab-first-for-diabetic-macular-edema/
https://gpcardio.org/en/2026-03-27_albiglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes-and-cardiovascular-disease-harmony-outcomes/
https://gpcardio.org/en/2026-03-27_albuminuria-testing-in-hypertension-and-diabetes/
https://gpcardio.org/en/2026-03-27_alert-based-computerized-decision-support-for-high-risk-hospitalized-patients-with-atrial-fibrillation-not-prescribed-anticoagulation/
https://gpcardio.org/en/2026-03-27_alirocumab-and-cardiovascular-outcomes-after-acute-coronary-syndrome/
https://gpcardio.org/en/2026-03-27_aliskiren-enalapril-or-aliskiren-and-enalapril-in-heart-failure/
https://gpcardio.org/en/2026-03-27_amphilimus-vs-zotarolimus-eluting-stents-in-patients-with-diabetes-mellitus-and-coronary-artery-disease/
https://gpcardio.org/en/2026-03-27_analysis-from-the-empa-reg-outcome-trial-indicates-empagliflozin-may-assist-in-preventing-the-progression-of-chronic-kidney-disease-in-patients-with-t/
https://gpcardio.org/en/2026-03-27_angiotensin-neprilysin-inhibition-in-acute-decompensated-heart-failure/
https://gpcardio.org/en/2026-03-27_anti-inflammatory-therapy-with-canakinumab-for-the-prevention-of-hospitalization-for-heart-failure/
https://gpcardio.org/en/2026-03-27_anticoagulant-in-atrial-fibrillation-patients-with-prior-intracranial-haemorrhage/
https://gpcardio.org/en/2026-03-27_anticoagulation-alone-or-with-antiaggregation-in-patients-with-coronary-artery-disease/
https://gpcardio.org/en/2026-03-27_anticoagulation-for-post-operative-atrial-fibrillation-after-isolated-coronary-artery-bypass-grafting/
https://gpcardio.org/en/2026-03-27_anticoagulation-in-device-detected-atrial-fibrillation-with-or-without-vascular-disease/
https://gpcardio.org/en/2026-03-27_anticoagulation-therapy-in-heart-failure-and-sinus-rhythm/
https://gpcardio.org/en/2026-03-27_anticoagulation-therapy-of-concomitant-conditions-and-early-rhythm-control-therapy/
https://gpcardio.org/en/2026-03-27_antihyperglycemic-and-blood-pressure-effects-of-empagliflozin-in-black-patients-with-type-2-diabetes-mellitus-and-hypertension/
https://gpcardio.org/en/2026-03-27_antiinflammatory-therapy-with-canakinumab-for-atherosclerotic-disease/
https://gpcardio.org/en/2026-03-27_antithrombotic-strategies-in-atrial-fibrillation-after-acs-and-or-pci/
https://gpcardio.org/en/2026-03-27_antithrombotic-therapy-in-patients-with-atrial-fibrillation-after-acute-coronary-syndromes-or-percutaneous-intervention/
https://gpcardio.org/en/2026-03-27_antithrombotic-therapy-in-patients-with-atrial-fibrillation-and-acute-coronary-syndrome-treated-medically-or-with-percutaneous-coronary-intervention-o/
https://gpcardio.org/en/2026-03-27_antithrombotic-therapy-in-patients-with-atrial-fibrillation-treated-with-oral-anticoagulation-undergoing-percutaneous-coronary-intervention/
https://gpcardio.org/en/2026-03-27_apixaban-5-mg-twice-daily-and-clinical-outcomes-in-patients-with-atrial-fibrillation-and-advanced-age-low-body-weight-or-high-creatinine/
https://gpcardio.org/en/2026-03-27_apixaban-compared-to-heparin-vitamin-k-antagonist-in-patients-with-atrial-fibrillation-scheduled-for-cardioversion/
https://gpcardio.org/en/2026-03-27_apixaban-in-patients-at-risk-of-stroke-undergoing-atrial-fibrillation-ablation/
https://gpcardio.org/en/2026-03-27_apixaban-or-warfarin-and-aspirin-or-placebo-after-acute-coronary-syndrome-or-percutaneous-coronary-intervention-in-patients-with-atrial-fibrillation-a/
https://gpcardio.org/en/2026-03-27_apixaban-versus-warfarin-in-patients-with-atrial-fibrillation-and-advanced-chronic-kidney-disease/
https://gpcardio.org/en/2026-03-27_apixaban-vs-aspirin-according-to-cha2ds2-vasc-score-in-subclinical-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_arterial-effects-of-canakinumab-in-patients-with-atherosclerosis-and-type-2-diabetes-or-glucose-intolerance/
https://gpcardio.org/en/2026-03-27_aspirin-versus-p2y12-inhibitors-with-anticoagulation-therapy-for-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_assessment-of-cardiac-energy-metabolism-function-and-physiology-in-patients-with-heart-failure-taking-empagliflozin/
https://gpcardio.org/en/2026-03-27_association-between-baseline-ldl-c-level-and-total-and-cardiovascular-mortality-after-ldl-c-lowering/
https://gpcardio.org/en/2026-03-27_association-between-gestational-diabetes-mellitus-and-hypertension/
https://gpcardio.org/en/2026-03-27_association-between-hemoglobin-levels-and-efficacy-of-intravenous-ferric-carboxymaltose-in-patients-with-acute-heart-failure-and-iron-deficiency/
https://gpcardio.org/en/2026-03-27_association-between-low-density-lipoprotein-cholesterol-lowering-genetic-variants-and-risk-of-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_association-between-lowering-ldl-c-and-cardiovascular-risk-reduction-among-different-therapeutic-interventions/
https://gpcardio.org/en/2026-03-27_association-between-sitagliptin-use-and-heart-failure-hospitalization-and-related-outcomes-in-type-2-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_association-between-sodium-glucose-cotransporter-2-inhibitors-and-risk-of-sudden-cardiac-death-or-ventricular-arrhythmias/
https://gpcardio.org/en/2026-03-27_association-between-use-of-sodium-glucose-cotransporter-2-inhibitors-glucagon-like-peptide-1-agonists-and-dipeptidyl-peptidase-4-inhibitors-with-all-c/
https://gpcardio.org/en/2026-03-27_association-of-aspirin-use-for-primary-prevention-with-cardiovascular-events-and-bleeding-events/
https://gpcardio.org/en/2026-03-27_association-of-cardiac-biomarkers-with-major-adverse-cardiovascular-events-in-high-risk-patients-with-diabetes/
https://gpcardio.org/en/2026-03-27_association-of-dapagliflozin-use-with-clinical-outcomes-and-the-introduction-of-uric-acid-lowering-therapy-and-colchicine-in-patients-with-heart-failu/
https://gpcardio.org/en/2026-03-27_association-of-empagliflozin-treatment-with-albuminuria-levels-in-patients-with-heart-failure/
https://gpcardio.org/en/2026-03-27_association-of-fenofibrate-therapy-with-long-term-cardiovascular-risk-in-statin-treated-patients-with-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_association-of-lipoproteins-insulin-resistance-and-rosuvastatin-with-incident-type-2-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_association-of-positive-airway-pressure-with-cardiovascular-events-and-death-in-adults-with-sleep-apnea/
https://gpcardio.org/en/2026-03-27_association-of-race-ethnicity-with-oral-anticoagulant-use-in-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_association-of-rivaroxaban-with-thromboembolic-events-in-patients-with-heart-failure-coronary-disease-and-sinus-rhythm/
https://gpcardio.org/en/2026-03-27_association-of-traditional-cardiovascular-risk-factors-with-venous-thromboembolism/
https://gpcardio.org/en/2026-03-27_associations-between-new-york-heart-association-classification-objective-measures-and-long-term-prognosis-in-mild-heart-failure/
https://gpcardio.org/en/2026-03-27_associations-of-dietary-cholesterol-serum-cholesterol-and-egg-consumption-with-overall-and-cause-specific-mortality/
https://gpcardio.org/en/2026-03-27_associations-of-empagliflozin-with-left-ventricular-volumes-mass-and-function-in-patients-with-heart-failure-and-reduced-ejection-fraction/
https://gpcardio.org/en/2026-03-27_associations-of-omega-3-fatty-acid-supplement-use-with-cardiovascular-disease-risks/
https://gpcardio.org/en/2026-03-27_atrial-fibrillation-and-dapagliflozin-efficacy-in-patients-with-preserved-or-mildly-reduced-ejection-fraction/
https://gpcardio.org/en/2026-03-27_atrial-fibrillation-and-semaglutide-effects-in-obesity-related-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_atrial-fibrillation-following-transcatheter-atrial-septal-defect-closure/
https://gpcardio.org/en/2026-03-27_atrial-fibrillation-prevention/
https://gpcardio.org/en/2026-03-27_attainment-of-targets-of-the-20-year-infancy-onset-dietary-intervention-and-blood-pressure-across-childhood-and-young-adulthood/
https://gpcardio.org/en/2026-03-27_bariatric-surgery-versus-intensive-medical-therapy-for-diabetes-5-year-outcomes/
https://gpcardio.org/en/2026-03-27_baseline-and-on-statin-treatment-lipoprotein-a-levels-for-prediction-of-cardiovascular-events/
https://gpcardio.org/en/2026-03-27_behavioral-counseling-interventions-to-promote-a-healthy-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-with-cardiovascula/
https://gpcardio.org/en/2026-03-27_behavioral-counseling-to-promote-a-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-without-cardiovascular-risk-fa/
https://gpcardio.org/en/2026-03-27_behavioral-counseling-to-promote-a-healthy-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-with-cardiovascular-risk-factors/
https://gpcardio.org/en/2026-03-27_beneficial-effect-of-a-polyphenol-rich-diet-on-cardiovascular-risk/
https://gpcardio.org/en/2026-03-27_benefit-of-adding-ezetimibe-to-statin-therapy-on-cardiovascular-outcomes-and-safety-in-patients-with-versus-without-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_benefit-of-switching-dual-antiplatelet-therapy-after-acute-coronary-syndrome/
https://gpcardio.org/en/2026-03-27_benefits-of-intensive-blood-pressure-treatment-in-patients-with-type-2-diabetes-mellitus-receiving-standard-but-not-intensive-glycemic-control/
https://gpcardio.org/en/2026-03-27_benefits-of-sodium-glucose-cotransporter-2-inhibitors-across-the-spectrum-of-cardiovascular-diseases/
https://gpcardio.org/en/2026-03-27_beta-blockers-for-heart-failure-with-reduced-mid-range-and-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_bilateral-versus-single-internal-thoracic-artery-grafts-at-10-years/
https://gpcardio.org/en/2026-03-27_biomarkers-of-inflammation-and-risk-of-cardiovascular-events-in-anticoagulated-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_bioresorbable-coronary-scaffold-thrombosis/
https://gpcardio.org/en/2026-03-27_bioresorbable-scaffolds-versus-metallic-stents-in-routine-pci/
https://gpcardio.org/en/2026-03-27_bivalirudin-or-heparin-in-patients-undergoing-invasive-management-of-acute-coronary-syndromes/
https://gpcardio.org/en/2026-03-27_bivalirudin-plus-a-high-dose-infusion-versus-heparin-monotherapy-in-patients-with-st-segment-elevation-myocardial-infarction-undergoing-primary-percut/
https://gpcardio.org/en/2026-03-27_bivalirudin-versus-heparin-during-pci-in-nstemi/
https://gpcardio.org/en/2026-03-27_bivalirudin-versus-heparin-monotherapy-in-myocardial-infarction/
https://gpcardio.org/en/2026-03-27_bivalirudin-vs-heparin-anticoagulation-in-stemi/
https://gpcardio.org/en/2026-03-27_blinded-withdrawal-of-long-term-randomized-treatment-with-empagliflozin-or-placebo-in-patients-with-heart-failure/
https://gpcardio.org/en/2026-03-27_blood-pressure-and-cardiorenal-outcomes-with-finerenone-in-chronic-kidney-disease-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_blood-pressure-and-cholesterol-lowering-in-persons-without-cardiovascular-disease/
https://gpcardio.org/en/2026-03-27_blood-pressure-and-risks-of-cognitive-impairment-and-dementia/
https://gpcardio.org/en/2026-03-27_blood-pressure-control-and-the-association-with-diabetes-mellitus-incidence/
https://gpcardio.org/en/2026-03-27_blood-pressure-lowering-for-prevention-of-cardiovascular-disease-and-death/
https://gpcardio.org/en/2026-03-27_blood-pressure-lowering-in-intermediate-risk-persons-without-cardiovascular-disease/
https://gpcardio.org/en/2026-03-27_body-mass-index-abdominal-fatness-and-heart-failure-incidence-and-mortality/
https://gpcardio.org/en/2026-03-27_body-weight-fluctuations-and-outcomes-in-coronary-disease/
https://gpcardio.org/en/2026-03-27_burden-of-atrial-high-rate-episodes-and-risk-of-stroke/
https://gpcardio.org/en/2026-03-27_bypass-surgery-or-stenting-for-left-main-coronary-artery-disease-in-patients-with-diabetes/
https://gpcardio.org/en/2026-03-27_can-glucose-lowering-medications-improve-outcomes-in-non-diabetic-heart-failure-patients-a-bayesian-network-meta-analysis/
https://gpcardio.org/en/2026-03-27_canagliflozin-and-cardiovascular-and-renal-events-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus-and-chronic-kidney-disease-in-primary-and-secondary-cardiovascular-pre/
https://gpcardio.org/en/2026-03-27_canagliflozin-and-heart-failure-in-type-2-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_canagliflozin-for-primary-and-secondary-prevention-of-cardiovascular-events/
https://gpcardio.org/en/2026-03-27_cardiac-and-metabolic-effects-of-dapagliflozin-in-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_cardiac-rehabilitation-and-physical-activity/
https://gpcardio.org/en/2026-03-27_cardiopulmonary-exercise-testing-and-efficacy-of-percutaneous-coronary-intervention/
https://gpcardio.org/en/2026-03-27_cardiovascular-and-limb-outcomes-in-patients-with-diabetes-and-peripheral-artery-disease/
https://gpcardio.org/en/2026-03-27_cardiovascular-and-metabolic-effects-of-angptl3-antisense-oligonucleotides/
https://gpcardio.org/en/2026-03-27_cardiovascular-consequences-of-discontinuing-low-dose-rivaroxaban-in-people-with-chronic-coronary-or-peripheral-artery-disease/
https://gpcardio.org/en/2026-03-27_cardiovascular-effects-and-safety-of-long-term-colchicine-treatment/
https://gpcardio.org/en/2026-03-27_cardiovascular-efficacy-and-safety-of-bococizumab-in-high-risk-patients/
https://gpcardio.org/en/2026-03-27_cardiovascular-events-associated-with-sglt-2-inhibitors-versus-other-glucose-lowering-drugs/
https://gpcardio.org/en/2026-03-27_cardiovascular-outcomes-according-to-urinary-albumin-and-kidney-disease-in-patients-with-type-2-diabetes-at-high-cardiovascular-risk/
https://gpcardio.org/en/2026-03-27_cardiovascular-outcomes-and-achieved-blood-pressure-in-patients-with-and-without-diabetes-at-high-cardiovascular-risk/
https://gpcardio.org/en/2026-03-27_cardiovascular-outcomes-and-safety-of-empagliflozin-in-patients-with-type-2-diabetes-mellitus-and-peripheral-artery-disease/
https://gpcardio.org/en/2026-03-27_cardiovascular-outcomes-in-grade-glycemia-reduction-approaches-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_cardiovascular-outcomes-with-semaglutide-by-severity-of-chronic-kidney-disease-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_cardiovascular-risk-reduction-with-icosapent-ethyl-for-hypertriglyceridemia/
https://gpcardio.org/en/2026-03-27_cardiovascular-safety-of-lorcaserin-in-overweight-or-obese-patients/
https://gpcardio.org/en/2026-03-27_catheter-ablation-as-first-line-treatment-for-paroxysmal-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_catheter-ablation-for-atrial-fibrillation-with-heart-failure/
https://gpcardio.org/en/2026-03-27_catheter-based-renal-denervation-in-patients-with-uncontrolled-hypertension-in-the-absence-of-antihypertensive-medications-spyral-htn-off-med/
https://gpcardio.org/en/2026-03-27_causes-of-death-following-pci-versus-cabg-in-complex-cad/
https://gpcardio.org/en/2026-03-27_challenging-the-hemodynamic-hypothesis-in-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_chest-pain-symptoms-during-myocardial-infarction-in-patients-with-and-without-diabetes/
https://gpcardio.org/en/2026-03-27_cholesterol-lowering-in-intermediate-risk-persons-without-cardiovascular-disease/
https://gpcardio.org/en/2026-03-27_clinical-and-echocardiographic-characteristics-and-cardiovascular-outcomes-according-to-diabetes-status-in-patients-with-heart-failure-and-preserved-e/
https://gpcardio.org/en/2026-03-27_clinical-and-pharmacological-effects-of-apixaban-dose-adjustment-in-the-aristotle-trial/
https://gpcardio.org/en/2026-03-27_clinical-benefit-of-evolocumab-by-severity-and-extent-of-coronary-artery-disease/
https://gpcardio.org/en/2026-03-27_clinical-efficacy-and-safety-of-achieving-very-low-ldl-cholesterol-concentrations-with-the-pcsk9-inhibitor-evolocumab/
https://gpcardio.org/en/2026-03-27_clinical-efficacy-of-intravitreal-aflibercept-versus-panretinal-photocoagulation-for-best-corrected-visual-acuity-in-patients-with-proliferative-diabe/
https://gpcardio.org/en/2026-03-27_clinically-significant-bleeding-with-low-dose-rivaroxaban-versus-aspirin-in-addition-to-p2y12-inhibition-in-acute-coronary-syndromes-gemini-acs-1/
https://gpcardio.org/en/2026-03-27_clopidogrel-and-aspirin-in-acute-ischemic-stroke-and-high-risk-tia/
https://gpcardio.org/en/2026-03-27_clopidogrel-versus-ticagrelor-for-antiplatelet-maintenance-in-diabetic-patients-treated-with-percutaneous-coronary-intervention/
https://gpcardio.org/en/2026-03-27_cognitive-function-in-a-randomized-trial-of-evolocumab/
https://gpcardio.org/en/2026-03-27_comparison-of-cardiovascular-outcomes-of-new-antihyperglycemic-agents-in-type-2-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_comparison-of-clinical-outcomes-and-adverse-events-associated-with-glucose-lowering-drugs-in-patients-with-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_comparison-of-dabigatran-and-warfarin-in-patients-with-atrial-fibrillation-and-valvular-heart-disease/
https://gpcardio.org/en/2026-03-27_comparison-of-major-adverse-cardiac-events-between-instantaneous-wave-free-ratio-and-fractional-flow-reserve-guided-strategy-in-patients-with-or-witho/
https://gpcardio.org/en/2026-03-27_comparisons-of-effectiveness-and-safety-between-on-label-dosing-off-label-underdosing-and-off-label-overdosing-in-asian-and-non-asian-atrial-fibrillat/
https://gpcardio.org/en/2026-03-27_complex-interaction-of-obesity-intentional-weight-loss-and-heart-failure/
https://gpcardio.org/en/2026-03-27_concomitant-oral-anticoagulant-and-nonsteroidal-anti-inflammatory-drug-therapy-in-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_continued-vs-interrupted-direct-oral-anticoagulants-at-the-time-of-device-surgery-in-patients-with-moderate-to-high-risk-of-arterial-thrombo-embolic-e/
https://gpcardio.org/en/2026-03-27_continuing-or-temporarily-stopping-prestroke-antihypertensive-medication-in-acute-stroke/
https://gpcardio.org/en/2026-03-27_continuous-dose-response-association-between-sedentary-time-and-risk-for-cardiovascular-disease/
https://gpcardio.org/en/2026-03-27_contributory-risk-and-management-of-comorbidities-of-hypertension-obesity-diabetes-mellitus-hyperlipidemia-and-metabolic-syndrome-in-chronic-heart-fai/
https://gpcardio.org/en/2026-03-27_coordinated-care-to-optimize-cardiovascular-preventive-therapies-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_coronary-artery-bypass-surgery-in-patients-with-ischemic-cardiomyopathy/
https://gpcardio.org/en/2026-03-27_coronary-ct-angiography-and-5-year-risk-of-myocardial-infarction/
https://gpcardio.org/en/2026-03-27_counseling-and-behavioral-interventions-for-healthy-weight-and-weight-gain-in-pregnancy/
https://gpcardio.org/en/2026-03-27_cryoballoon-ablation-vs-antiarrhythmic-drugs/
https://gpcardio.org/en/2026-03-27_cryoballoon-or-radiofrequency-ablation-for-atrial-fibrillation-assessed-by-continuous-monitoring/
https://gpcardio.org/en/2026-03-27_cryoballoon-or-radiofrequency-ablation-for-paroxysmal-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_cryoballoon-pulmonary-vein-isolation-as-first-line-treatment-for-typical-atrial-flutter/
https://gpcardio.org/en/2026-03-27_culturally-adapted-lifestyle-intervention-for-south-asian-adults-with-cardiovascular-risk-factors/
https://gpcardio.org/en/2026-03-27_dabigatran-dual-therapy-with-ticagrelor-or-clopidogrel-after-percutaneous-coronary-intervention-in-atrial-fibrillation-patients-with-or-without-acute-/
https://gpcardio.org/en/2026-03-27_dabigatran-in-patients-with-myocardial-injury-after-non-cardiac-surgery-manage/
https://gpcardio.org/en/2026-03-27_dapagliflozin-and-cardiac-kidney-and-limb-outcomes-in-patients-with-and-without-peripheral-artery-disease-in-declare-timi-58/
https://gpcardio.org/en/2026-03-27_dapagliflozin-and-cardiovascular-outcomes-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_dapagliflozin-and-diuretic-use-in-patients-with-heart-failure-and-reduced-ejection-fraction-in-dapa-hf/
https://gpcardio.org/en/2026-03-27_dapagliflozin-and-kidney-outcomes-in-patients-with-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_dapagliflozin-and-right-ventricular-pulmonary-vascular-interaction-in-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_dapagliflozin-enhances-arterial-and-venous-compliance-during-exercise-in-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_dapagliflozin-vs-metolazone-in-heart-failure-resistant-to-loop-diuretics/
https://gpcardio.org/en/2026-03-27_de-escalation-to-ticagrelor-monotherapy-versus-12-months-of-dual-antiplatelet-therapy-in-patients-with-and-without-acute-coronary-syndromes/
https://gpcardio.org/en/2026-03-27_deep-endotyping-of-renal-damage-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_deep-lipidomics-in-human-plasma/
https://gpcardio.org/en/2026-03-27_defibrillator-implantation-in-patients-with-nonischemic-systolic-heart-failure/
https://gpcardio.org/en/2026-03-27_development-and-validation-of-a-prediction-rule-for-benefit-and-harm-of-dual-antiplatelet-therapy-beyond-1-year-after-percutaneous-coronary-interventi/
https://gpcardio.org/en/2026-03-27_diabetes-mellitus-and-prevention-of-late-myocardial-infarction-after-coronary-stenting-in-the-randomized-dual-antiplatelet-therapy-study/
https://gpcardio.org/en/2026-03-27_diabetes-mellitus-and-risk-of-new-onset-and-recurrent-heart-failure/
https://gpcardio.org/en/2026-03-27_diabetes-related-factors-and-the-effects-of-ticagrelor-plus-aspirin-in-the-themis-and-themis-pci-trials/
https://gpcardio.org/en/2026-03-27_diagnosing-heart-failure-in-primary-care/
https://gpcardio.org/en/2026-03-27_diagnostic-accuracy-of-natriuretic-peptide-screening-for-left-ventricular-systolic-dysfunction-in-the-community/
https://gpcardio.org/en/2026-03-27_diet-and-risk-of-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_dietary-approaches-to-stop-hypertension-dietary-intervention-improves-blood-pressure-and-vascular-health-in-youth-with-elevated-blood-pressure/
https://gpcardio.org/en/2026-03-27_dietary-cholesterol-and-cardiovascular-risk/
https://gpcardio.org/en/2026-03-27_differential-blood-pressure-effects-of-ibuprofen-naproxen-and-celecoxib-in-patients-with-arthritis/
https://gpcardio.org/en/2026-03-27_differing-associations-for-sport-versus-occupational-physical-activity-and-cardiovascular-risk/
https://gpcardio.org/en/2026-03-27_direct-oral-anticoagulants-halve-thromboembolic-events-after-cardioversion-of-af-compared-with-warfarin/
https://gpcardio.org/en/2026-03-27_direct-oral-anticoagulants-in-addition-to-antiplatelet-therapy-for-secondary-prevention-after-acute-coronary-syndromes/
https://gpcardio.org/en/2026-03-27_direct-oral-anticoagulants-in-patients-with-atrial-fibrillation-and-valvular-heart-disease-other-than-significant-mitral-stenosis-and-mechanical-valve/
https://gpcardio.org/en/2026-03-27_direct-oral-anticoagulants-versus-no-anticoagulation-for-the-prevention-of-stroke-in-survivors-of-intracerebral-haemorrhage-with-atrial-fibrillation-p/
https://gpcardio.org/en/2026-03-27_dose-reduction-of-edoxaban-in-patients-80-years-and-older-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_dose-response-association-between-physical-activity-and-incident-hypertension/
https://gpcardio.org/en/2026-03-27_double-kissing-crush-versus-provisional-stenting-for-left-main-distal-bifurcation-lesions/
https://gpcardio.org/en/2026-03-27_drug-eluting-or-bare-metal-stents-for-coronary-artery-disease/
https://gpcardio.org/en/2026-03-27_drug-eluting-stents-in-elderly-patients-with-coronary-artery-disease-senior/
https://gpcardio.org/en/2026-03-27_drug-treatment-effects-on-outcomes-in-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_dual-antiplatelet-therapy-versus-aspirin-monotherapy-in-diabetics-with-multivessel-disease-undergoing-cabg/
https://gpcardio.org/en/2026-03-27_dual-antithrombotic-therapy-with-dabigatran-after-pci-in-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_dual-vs-single-cardioversion-of-atrial-fibrillation-in-patients-with-obesity/
https://gpcardio.org/en/2026-03-27_duration-of-dual-antiplatelet-therapy/
https://gpcardio.org/en/2026-03-27_early-invasive-versus-non-invasive-treatment-in-patients-with-non-st-elevation-acute-coronary-syndrome-frisc-ii/
https://gpcardio.org/en/2026-03-27_early-versus-late-initiation-of-direct-oral-anticoagulants-after-ischemic-stroke-in-people-with-atrial-fibrillation-and-hemorrhagic-transformation/
https://gpcardio.org/en/2026-03-27_echo-guided-left-ventricular-assist-device-speed-optimisation-for-exercise-maximisation/
https://gpcardio.org/en/2026-03-27_edetate-disodium-based-chelation-for-patients-with-a-previous-myocardial-infarction-and-diabetes/
https://gpcardio.org/en/2026-03-27_edoxaban-antithrombotic-therapy-for-atrial-fibrillation-and-stable-coronary-artery-disease/
https://gpcardio.org/en/2026-03-27_edoxaban-for-the-prevention-of-thromboembolism-in-patients-with-atrial-fibrillation-and-bioprosthetic-valves/
https://gpcardio.org/en/2026-03-27_edoxaban-versus-enoxaparin-warfarin-in-patients-undergoing-cardioversion-of-atrial-fibrillation-ensure-af/
https://gpcardio.org/en/2026-03-27_edoxaban-versus-warfarin-in-atrial-fibrillation-patients-at-risk-of-falling/
https://gpcardio.org/en/2026-03-27_effect-of-15-mg-edoxaban-on-clinical-outcomes-in-3-age-strata-in-older-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_effect-of-3-2-drug-combinations-of-antihypertensive-therapies-on-blood-pressure-variability-in-black-african-patients/
https://gpcardio.org/en/2026-03-27_effect-of-5-years-of-exercise-training-on-the-cardiovascular-risk-profile-of-older-adults/
https://gpcardio.org/en/2026-03-27_effect-of-a-collaborative-care-model-on-depressive-symptoms-and-glycated-hemoglobin-blood-pressure-and-serum-cholesterol-among-patients-with-depressio/
https://gpcardio.org/en/2026-03-27_effect-of-a-digital-intervention-on-depressive-symptoms-in-patients-with-comorbid-hypertension-or-diabetes-in-brazil-and-peru/
https://gpcardio.org/en/2026-03-27_effect-of-a-home-based-wearable-continuous-ecg-monitoring-patch-on-detection-of-undiagnosed-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_effect-of-a-multi-domain-lifestyle-intervention-on-cardiovascular-risk-in-older-people/
https://gpcardio.org/en/2026-03-27_effect-of-aficamten-vs-metoprolol-on-patient-reported-health-status-in-obstructive-hypertrophic-cardiomyopathy/
https://gpcardio.org/en/2026-03-27_effect-of-aldosterone-antagonism-on-exercise-tolerance-in-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_effect-of-apabetalone-added-to-standard-therapy-on-major-adverse-cardiovascular-events-in-patients-with-recent-acute-coronary-syndrome-and-type-2-diab/
https://gpcardio.org/en/2026-03-27_effect-of-bardoxolone-methyl-on-the-urine-albumin-to-creatinine-ratio-in-patients-with-type-2-diabetes-and-stage-4-chronic-kidney-disease/
https://gpcardio.org/en/2026-03-27_effect-of-caloric-restriction-or-aerobic-exercise-training-on-peak-oxygen-consumption-and-quality-of-life-in-obese-older-patients-with-heart-failure-w/
https://gpcardio.org/en/2026-03-27_effect-of-catheter-ablation-vs-antiarrhythmic-drug-therapy-on-mortality-stroke-bleeding-and-cardiac-arrest-among-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_effect-of-catheter-ablation-vs-medical-therapy-on-quality-of-life-among-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_effect-of-current-dietary-recommendations-on-weight-loss-and-cardiovascular-risk-factors/
https://gpcardio.org/en/2026-03-27_effect-of-dapagliflozin-on-cardiovascular-outcomes-according-to-baseline-kidney-function-and-albuminuria-status-in-patients-with-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_effect-of-distinct-lifestyle-interventions-on-mobilization-of-fat-storage-pools/
https://gpcardio.org/en/2026-03-27_effect-of-empagliflozin-on-circulating-proteomics-in-heart-failure/
https://gpcardio.org/en/2026-03-27_effect-of-empagliflozin-on-exercise-ability-and-symptoms-in-heart-failure-patients-with-reduced-and-preserved-ejection-fraction-with-and-without-type-/
https://gpcardio.org/en/2026-03-27_effect-of-empagliflozin-on-heart-failure-outcomes-after-acute-myocardial-infarction/
https://gpcardio.org/en/2026-03-27_effect-of-empagliflozin-on-hemodynamics-in-patients-with-heart-failure-and-reduced-ejection-fraction/
https://gpcardio.org/en/2026-03-27_effect-of-empagliflozin-on-left-ventricular-volumes-in-patients-with-type-2-diabetes-or-prediabetes-and-heart-failure-with-reduced-ejection-fraction-s/
https://gpcardio.org/en/2026-03-27_effect-of-evolocumab-on-progression-of-coronary-disease-in-statin-treated-patients/
https://gpcardio.org/en/2026-03-27_effect-of-exercise-training-on-ambulatory-blood-pressure-among-patients-with-resistant-hypertension/
https://gpcardio.org/en/2026-03-27_effect-of-initial-management-with-aflibercept-vs-laser-photocoagulation-vs-observation-on-vision-loss-among-patients-with-diabetic-macular-edema-invol/
https://gpcardio.org/en/2026-03-27_effect-of-inorganic-nitrite-vs-placebo-on-exercise-capacity-among-patients-with-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_effect-of-intensive-blood-pressure-lowering-on-left-ventricular-hypertrophy-in-patients-with-hypertension/
https://gpcardio.org/en/2026-03-27_effect-of-intensive-blood-pressure-treatment-on-patient-reported-outcomes/
https://gpcardio.org/en/2026-03-27_effect-of-intensive-vs-standard-blood-pressure-control-on-probable-dementia/
https://gpcardio.org/en/2026-03-27_effect-of-interleukin-1β-inhibition-with-canakinumab-on-incident-lung-cancer-in-patients-with-atherosclerosis/
https://gpcardio.org/en/2026-03-27_effect-of-intravitreous-aflibercept-vs-vitrectomy-with-panretinal-photocoagulation-on-visual-acuity-in-patients-with-vitreous-hemorrhage-from-prolifer/
https://gpcardio.org/en/2026-03-27_effect-of-iron-isomaltoside-on-skeletal-muscle-energetics-in-patients-with-chronic-heart-failure-and-iron-deficiency/
https://gpcardio.org/en/2026-03-27_effect-of-laparoscopic-sleeve-gastrectomy-vs-laparoscopic-roux-en-y-gastric-bypass-on-weight-loss-at-5-years-among-patients-with-morbid-obesity/
https://gpcardio.org/en/2026-03-27_effect-of-linagliptin-vs-placebo-on-major-cardiovascular-events-in-adults-with-type-2-diabetes-and-high-cardiovascular-and-renal-risk/
https://gpcardio.org/en/2026-03-27_effect-of-liraglutide-on-cardiovascular-events-in-patients-with-type-2-diabetes-mellitus-and-polyvascular-disease/
https://gpcardio.org/en/2026-03-27_effect-of-long-term-metformin-and-lifestyle-in-the-diabetes-prevention-program-and-its-outcome-study-on-coronary-artery-calcium/
https://gpcardio.org/en/2026-03-27_effect-of-lorcaserin-on-prevention-and-remission-of-type-2-diabetes-in-overweight-and-obese-patients-camellia-timi-61/
https://gpcardio.org/en/2026-03-27_effect-of-morning-exercise-with-or-without-breaks-in-prolonged-sitting-on-blood-pressure-in-older-overweight-obese-adults/
https://gpcardio.org/en/2026-03-27_effect-of-naltrexone-bupropion-on-major-adverse-cardiovascular-events-in-overweight-and-obese-patients-with-cardiovascular-risk-factors/
https://gpcardio.org/en/2026-03-27_effect-of-natriuretic-peptide-guided-therapy-on-hospitalization-or-cardiovascular-mortality-in-high-risk-patients-with-heart-failure-and-reduced-eject/
https://gpcardio.org/en/2026-03-27_effect-of-neladenoson-bialanate-on-exercise-capacity-among-patients-with-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_effect-of-oral-iron-repletion-on-exercise-capacity-in-patients-with-heart-failure-with-reduced-ejection-fraction-and-iron-deficiency/
https://gpcardio.org/en/2026-03-27_effect-of-renal-denervation-on-blood-pressure-in-the-presence-of-antihypertensive-drugs/
https://gpcardio.org/en/2026-03-27_effect-of-sacubitril-valsartan-vs-standard-medical-therapies-on-plasma-nt-probnp-concentration-and-submaximal-exercise-capacity-in-patients-with-heart/
https://gpcardio.org/en/2026-03-27_effect-of-semaglutide-on-cardiac-structure-and-function-in-patients-with-obesity-related-heart-failure/
https://gpcardio.org/en/2026-03-27_effect-of-semaglutide-on-epicardial-adipose-tissue-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_effect-of-sex-on-sodium-glucose-co-transporter-2-antagonists-and-glucagon-like-peptide-1-agonists-in-heart-failure/
https://gpcardio.org/en/2026-03-27_effect-of-statins-and-non-statin-ldl-lowering-medications-on-cardiovascular-outcomes-in-secondary-prevention/
https://gpcardio.org/en/2026-03-27_effect-of-the-reg1-anticoagulation-system-versus-bivalirudin-on-outcomes-after-percutaneous-coronary-intervention-regulate-pci/
https://gpcardio.org/en/2026-03-27_effect-of-trimetazidine-dihydrochloride-therapy-on-exercise-capacity-in-patients-with-nonobstructive-hypertrophic-cardiomyopathy/
https://gpcardio.org/en/2026-03-27_effect-of-ularitide-on-cardiovascular-mortality-in-acute-heart-failure/
https://gpcardio.org/en/2026-03-27_effect-of-vitamin-d-supplementation-omega-3-fatty-acid-supplementation-or-a-strength-training-exercise-program-on-clinical-outcomes-in-older-adults/
https://gpcardio.org/en/2026-03-27_effectiveness-of-a-text-based-gamification-intervention-to-improve-physical-activity-among-postpartum-individuals-with-hypertensive-disorders-of-pregn/
https://gpcardio.org/en/2026-03-27_effects-of-a-digital-intervention-to-improve-dash-and-blood-pressure-among-us-adults/
https://gpcardio.org/en/2026-03-27_effects-of-an-intervention-to-improve-evidence-based-care-for-people-with-diabetes-and-cardiovascular-disease-across-sex-race-and-ethnicity-subgroups/
https://gpcardio.org/en/2026-03-27_effects-of-anacetrapib-in-patients-with-atherosclerotic-vascular-disease/
https://gpcardio.org/en/2026-03-27_effects-of-aspirin-for-primary-prevention-in-persons-with-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_effects-of-bariatric-surgery-in-obese-patients-with-hypertension/
https://gpcardio.org/en/2026-03-27_effects-of-bariatric-surgery-versus-medical-therapy-on-the-24-hour-ambulatory-blood-pressure-and-the-prevalence-of-resistant-hypertension/
https://gpcardio.org/en/2026-03-27_effects-of-blood-pressure-lowering-on-clinical-outcomes-according-to-baseline-blood-pressure-and-cardiovascular-risk-in-patients-with-type-2-diabetes-/
https://gpcardio.org/en/2026-03-27_effects-of-canagliflozin-in-patients-with-type-2-diabetes-and-chronic-heart-failure/
https://gpcardio.org/en/2026-03-27_effects-of-canagliflozin-on-amino-terminal-pro-b-type-natriuretic-peptide/
https://gpcardio.org/en/2026-03-27_effects-of-canagliflozin-on-cardiovascular-biomarkers-in-older-adults-with-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_effects-of-canagliflozin-on-heart-failure-outcomes-associated-with-preserved-and-reduced-ejection-fraction-in-type-2-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_effects-of-cuisine-based-chinese-heart-healthy-diet-in-lowering-blood-pressure-among-adults-in-china/
https://gpcardio.org/en/2026-03-27_effects-of-dabigatran-according-to-age-in-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_effects-of-diet-and-sodium-reduction-on-cardiac-injury-strain-and-inflammation/
https://gpcardio.org/en/2026-03-27_effects-of-different-dietary-interventions-on-blood-pressure/
https://gpcardio.org/en/2026-03-27_effects-of-empagliflozin-on-risk-for-cardiovascular-death-and-heart-failure-hospitalization-across-the-spectrum-of-heart-failure-risk-in-the-empa-reg-/
https://gpcardio.org/en/2026-03-27_effects-of-experimental-sleep-restriction-on-ambulatory-and-sleep-blood-pressure-in-healthy-young-adults/
https://gpcardio.org/en/2026-03-27_effects-of-intensive-blood-pressure-control-on-cardiovascular-and-cognitive-outcomes-in-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_effects-of-intensive-blood-pressure-lowering-on-cardiovascular-and-renal-outcomes/
https://gpcardio.org/en/2026-03-27_effects-of-lifestyle-modification-on-patients-with-resistant-hypertension/
https://gpcardio.org/en/2026-03-27_effects-of-liraglutide-on-cardiovascular-outcomes-in-patients-with-diabetes-with-or-without-heart-failure/
https://gpcardio.org/en/2026-03-27_effects-of-liraglutide-on-cardiovascular-outcomes-in-patients-with-type-2-diabetes-mellitus-with-or-without-history-of-myocardial-infarction-or-stroke/
https://gpcardio.org/en/2026-03-27_effects-of-liraglutide-on-clinical-stability-among-patients-with-advanced-heart-failure-and-reduced-ejection-fraction/
https://gpcardio.org/en/2026-03-27_effects-of-liraglutide-versus-placebo-on-cardiovascular-events-in-patients-with-type-2-diabetes-mellitus-and-chronic-kidney-disease/
https://gpcardio.org/en/2026-03-27_effects-of-n-3-fatty-acid-supplements-in-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_effects-of-once-weekly-exenatide-on-cardiovascular-outcomes-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_effects-of-sodium-reduction-and-the-dash-diet-in-relation-to-baseline-blood-pressure/
https://gpcardio.org/en/2026-03-27_effects-of-sotagliflozin-on-health-status-in-patients-with-worsening-heart-failure/
https://gpcardio.org/en/2026-03-27_effects-of-the-nonsteroidal-mra-finerenone-with-and-without-concomitant-sglt2-inhibitor-use-in-heart-failure/
https://gpcardio.org/en/2026-03-27_effects-of-the-selective-sodium-glucose-cotransporter-2-inhibitor-empagliflozin-on-vascular-function-and-central-hemodynamics-in-patients-with-type-2-/
https://gpcardio.org/en/2026-03-27_effects-of-tirzepatide-on-the-clinical-trajectory-of-patients-with-heart-failure-preserved-ejection-fraction-and-obesity/
https://gpcardio.org/en/2026-03-27_effects-on-mortality-and-major-bleeding-of-radial-versus-femoral-artery-access-for-coronary-angiography-or-percutaneous-coronary-intervention/
https://gpcardio.org/en/2026-03-27_efficacy-and-safety-of-a-novel-low-dose-triple-single-pill-combination-compared-with-placebo-for-initial-treatment-of-hypertension/
https://gpcardio.org/en/2026-03-27_efficacy-and-safety-of-apixaban-compared-with-warfarin-in-patients-with-atrial-fibrillation-in-relation-to-renal-function-over-time/
https://gpcardio.org/en/2026-03-27_efficacy-and-safety-of-dapagliflozin-according-to-background-use-of-cardiovascular-medications-in-patients-with-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_efficacy-and-safety-of-degludec-versus-glargine-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_efficacy-and-safety-of-further-lowering-of-low-density-lipoprotein-cholesterol-in-patients-starting-with-very-low-levels/
https://gpcardio.org/en/2026-03-27_efficacy-and-safety-of-left-atrial-appendage-closure-versus-medical-treatment-in-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_efficacy-and-safety-of-ly3298176-a-novel-dual-gip-and-glp-1-receptor-agonist-in-patients-with-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_efficacy-and-safety-of-non-vitamin-k-antagonist-oral-anticoagulants-versus-warfarin-across-the-spectrum-of-body-mass-index-and-body-weight/
https://gpcardio.org/en/2026-03-27_efficacy-and-safety-of-reduced-dose-non-vitamin-k-antagonist-oral-anticoagulants-in-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_efficacy-and-safety-of-rivaroxaban-compared-with-vitamin-k-antagonists-for-peri-procedural-anticoagulation-in-catheter-ablation-of-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_efficacy-and-safety-of-sglt2-inhibitors-in-heart-failure/
https://gpcardio.org/en/2026-03-27_efficacy-and-safety-of-statin-therapy-in-older-people/
https://gpcardio.org/en/2026-03-27_efficacy-and-safety-of-the-use-of-non-vitamin-k-antagonist-oral-anticoagulants-in-patients-with-nonvalvular-atrial-fibrillation-and-concomitant-aspiri/
https://gpcardio.org/en/2026-03-27_efficacy-and-tolerability-of-evolocumab-vs-ezetimibe-in-patients-with-muscle-related-statin-intolerance/
https://gpcardio.org/en/2026-03-27_efficacy-durability-and-safety-of-intravitreal-faricimab-with-extended-dosing-up-to-every-16-weeks-in-patients-with-diabetic-macular-oedema-yosemite-a/
https://gpcardio.org/en/2026-03-27_efficacy-of-a-digital-therapeutics-system-in-the-management-of-essential-hypertension/
https://gpcardio.org/en/2026-03-27_efficacy-of-catheter-ablation-for-atrial-fibrillation-in-heart-failure/
https://gpcardio.org/en/2026-03-27_efficacy-of-ertugliflozin-on-heart-failure-related-events-in-patients-with-type-2-diabetes-mellitus-and-established-atherosclerotic-cardiovascular-dis/
https://gpcardio.org/en/2026-03-27_efficacy-of-self-monitored-blood-pressure-with-or-without-telemonitoring-for-titration-of-antihypertensive-medication-tasminh4/
https://gpcardio.org/en/2026-03-27_efficacy-of-semaglutide-by-sex-in-obesity-related-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_efficacy-of-telemedical-interventional-management-in-patients-with-heart-failure-tim-hf2/
https://gpcardio.org/en/2026-03-27_electronic-health-record-alerts-for-management-of-heart-failure-with-reduced-ejection-fraction-in-hospitalized-patients/
https://gpcardio.org/en/2026-03-27_eligibility-of-outpatients-with-chronic-heart-failure-for-sodium-glucose-co-transporter-2-inhibitors/
https://gpcardio.org/en/2026-03-27_eligibility-of-sodium-glucose-co-transporter-2-inhibitors-among-patients-with-diabetes-mellitus-admitted-for-heart-failure/
https://gpcardio.org/en/2026-03-27_empagliflozin-and-clinical-outcomes-in-patients-with-type-2-diabetes-mellitus-established-cardiovascular-disease-and-chronic-kidney-disease/
https://gpcardio.org/en/2026-03-27_empagliflozin-and-left-ventricular-remodeling-in-people-without-diabetes/
https://gpcardio.org/en/2026-03-27_empagliflozin-and-progression-of-kidney-disease-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_empagliflozin-effects-on-pulmonary-artery-pressure-in-patients-with-heart-failure/
https://gpcardio.org/en/2026-03-27_empagliflozin-improves-cardiovascular-and-renal-outcomes-in-heart-failure-irrespective-of-systolic-blood-pressure/
https://gpcardio.org/en/2026-03-27_empagliflozin-in-heart-failure/
https://gpcardio.org/en/2026-03-27_empagliflozin-in-patients-with-heart-failure-reduced-ejection-fraction-and-volume-overload/
https://gpcardio.org/en/2026-03-27_empagliflozin-reduced-mortality-and-hospitalization-for-heart-failure-across-the-spectrum-of-cardiovascular-risk-in-the-empa-reg-outcome-trial/
https://gpcardio.org/en/2026-03-27_empagliflozin-reduces-markers-of-acute-kidney-injury-in-patients-with-acute-decompensated-heart-failure/
https://gpcardio.org/en/2026-03-27_endovascular-ultrasound-renal-denervation-to-treat-hypertension-radiance-htn-solo/
https://gpcardio.org/en/2026-03-27_epidemiology-of-cerebral-microbleeds-and-risk-of-adverse-outcomes-in-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_ertugliflozin-for-functional-mitral-regurgitation-associated-with-heart-failure/
https://gpcardio.org/en/2026-03-27_estimating-individual-lifetime-benefit-and-bleeding-risk-of-adding-rivaroxaban-to-aspirin-for-patients-with-stable-cardiovascular-disease/
https://gpcardio.org/en/2026-03-27_european-heart-rhythm-association-ehra-european-association-of-cardiovascular-prevention-and-rehabilitation-eacpr-position-paper-on-how-to-prevent-atr/
https://gpcardio.org/en/2026-03-27_evacetrapib-and-cardiovascular-outcomes-in-high-risk-vascular-disease/
https://gpcardio.org/en/2026-03-27_evaluating-the-effects-of-canagliflozin-on-cardiovascular-and-renal-events-in-patients-with-type-2-diabetes-mellitus-and-chronic-kidney-disease-accord/
https://gpcardio.org/en/2026-03-27_evaluation-of-macitentan-in-patients-with-eisenmenger-syndrome/
https://gpcardio.org/en/2026-03-27_everolimus-eluting-bioresorbable-vascular-scaffolds-versus-everolimus-eluting-metallic-stents/
https://gpcardio.org/en/2026-03-27_everolimus-eluting-stents-or-bypass-surgery-for-left-main-coronary-artery-disease/
https://gpcardio.org/en/2026-03-27_evolocumab-and-clinical-outcomes-in-patients-with-cardiovascular-disease/
https://gpcardio.org/en/2026-03-27_executive-summary-of-the-kdigo-2021-clinical-practice-guideline-for-the-management-of-blood-pressure-in-chronic-kidney-disease/
https://gpcardio.org/en/2026-03-27_exercise-based-cardiac-rehabilitation-for-coronary-heart-disease/
https://gpcardio.org/en/2026-03-27_exercise-benefits-in-pulmonary-hypertension/
https://gpcardio.org/en/2026-03-27_exercise-electrocardiography-and-computed-tomography-coronary-angiography-for-patients-with-suspected-stable-angina-pectoris/
https://gpcardio.org/en/2026-03-27_exercise-haemodynamics-in-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_exercise-intervention-improves-quality-of-life-in-older-adults-after-myocardial-infarction/
https://gpcardio.org/en/2026-03-27_exercise-training-improves-peak-oxygen-consumption-and-haemodynamics-in-patients-with-severe-pulmonary-arterial-hypertension-and-inoperable-chronic-th/
https://gpcardio.org/en/2026-03-27_exercise-training-in-patients-with-chronic-heart-failure-and-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_exploring-the-relationship-between-efpeglenatide-dose-and-cardiovascular-outcomes-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_extrapolating-long-term-event-free-and-overall-survival-with-dapagliflozin-in-patients-with-heart-failure-and-reduced-ejection-fraction/
https://gpcardio.org/en/2026-03-27_fatal-or-irreversible-bleeding-and-ischemic-events-with-rivaroxaban-in-acute-coronary-syndrome/
https://gpcardio.org/en/2026-03-27_ferric-carboxymaltose-and-exercise-capacity-in-heart-failure-with-preserved-ejection-fraction-and-iron-deficiency/
https://gpcardio.org/en/2026-03-27_ferric-carboxymaltose-for-the-treatment-of-iron-deficient-heart-failure-patients/
https://gpcardio.org/en/2026-03-27_finerenone-and-left-ventricular-hypertrophy-in-chronic-kidney-disease-and-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_finerenone-obesity-and-heart-failure-with-mildly-reduced-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_finerenone-reduces-new-onset-atrial-fibrillation-in-patients-with-chronic-kidney-disease-and-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_five-year-outcomes-after-off-pump-or-on-pump-coronary-artery-bypass-grafting/
https://gpcardio.org/en/2026-03-27_five-year-outcomes-with-pci-guided-by-fractional-flow-reserve/
https://gpcardio.org/en/2026-03-27_fixed-low-dose-triple-combination-antihypertensive-medication-vs-usual-care-for-blood-pressure-control-in-patients-with-mild-to-moderate-hypertension-/
https://gpcardio.org/en/2026-03-27_fractional-flow-reserve-and-instantaneous-wave-free-ratio-as-predictors-of-the-placebo-controlled-response-to-percutaneous-coronary-intervention-in-st/
https://gpcardio.org/en/2026-03-27_fractional-flow-reserve-guided-multivessel-angioplasty-in-myocardial-infarction/
https://gpcardio.org/en/2026-03-27_frailty-status-modifies-the-efficacy-of-exercise-training-among-patients-with-chronic-heart-failure-and-reduced-ejection-fraction/
https://gpcardio.org/en/2026-03-27_frequency-of-evidence-based-screening-for-retinopathy-in-type-1-diabetes/
https://gpcardio.org/en/2026-03-27_genetic-and-pharmacologic-inactivation-of-angptl3-and-cardiovascular-disease/
https://gpcardio.org/en/2026-03-27_genetic-obesity-and-the-risk-of-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_genetics-lifestyle-and-low-density-lipoprotein-cholesterol-in-young-and-apparently-healthy-women/
https://gpcardio.org/en/2026-03-27_global-prevalence-of-resistant-hypertension/
https://gpcardio.org/en/2026-03-27_glycemic-control-cardiac-autoimmunity-and-long-term-risk-of-cardiovascular-disease-in-type-1-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_group-medical-visit-and-microfinance-intervention-for-patients-with-diabetes-or-hypertension-in-kenya/
https://gpcardio.org/en/2026-03-27_guided-de-escalation-of-antiplatelet-treatment-in-patients-with-acute-coronary-syndrome-undergoing-percutaneous-coronary-intervention-tropical-acs/
https://gpcardio.org/en/2026-03-27_guidelines-for-listing-candidates-for-heart-transplant/
https://gpcardio.org/en/2026-03-27_heart-failure-after-ischemic-stroke-or-transient-ischemic-attack-in-insulin-resistant-patients-without-diabetes-mellitus-treated-with-pioglitazone/
https://gpcardio.org/en/2026-03-27_hemocompatibility-related-outcomes-in-the-momentum-3-trial-at-6-months/
https://gpcardio.org/en/2026-03-27_high-intensity-interval-training-in-patients-with-heart-failure-with-reduced-ejection-fraction/
https://gpcardio.org/en/2026-03-27_hypertension-control-in-adults-with-diabetes-mellitus-and-recurrent-cardiovascular-events/
https://gpcardio.org/en/2026-03-27_hypertension-pharmacological-treatment-in-adults/
https://gpcardio.org/en/2026-03-27_hypoglycemia-and-elevated-troponin-in-patients-with-diabetes-and-coronary-artery-disease/
https://gpcardio.org/en/2026-03-27_il-interleukin-1-receptor-antagonist-increases-ang-angiotensin-1-7-and-decreases-blood-pressure-in-obese-individuals/
https://gpcardio.org/en/2026-03-27_impact-of-coronary-microvascular-dysfunction-in-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_impact-of-empagliflozin-on-blood-pressure-in-patients-with-type-2-diabetes-mellitus-and-hypertension-by-background-antihypertensive-medication/
https://gpcardio.org/en/2026-03-27_impact-of-exercise-rehabilitation-on-exercise-capacity-and-quality-of-life-in-heart-failure/
https://gpcardio.org/en/2026-03-27_impact-of-malnutrition-in-patients-with-heart-failure-and-secondary-mitral-regurgitation/
https://gpcardio.org/en/2026-03-27_impact-of-multiple-obesity-metrics-on-hypertensive-disorders-of-pregnancy/
https://gpcardio.org/en/2026-03-27_impact-of-primary-care-involvement-and-setting-on-multidisciplinary-heart-failure-management/
https://gpcardio.org/en/2026-03-27_impact-of-renal-function-on-outcomes-with-edoxaban-in-the-engage-af-timi-48-trial/
https://gpcardio.org/en/2026-03-27_impact-of-sglt2-inhibition-on-markers-of-reverse-cardiac-remodelling-in-heart-failure/
https://gpcardio.org/en/2026-03-27_impact-of-the-syntax-scores-i-and-ii-in-patients-with-diabetes-and-multivessel-coronary-disease/
https://gpcardio.org/en/2026-03-27_impact-of-weight-on-the-efficacy-and-safety-of-direct-acting-oral-anticoagulants-in-patients-with-non-valvular-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_inclisiran-in-patients-at-high-cardiovascular-risk-with-elevated-ldl-cholesterol/
https://gpcardio.org/en/2026-03-27_indirect-comparison-of-sglt2-inhibitors-in-patients-with-established-heart-failure/
https://gpcardio.org/en/2026-03-27_individualized-nutritional-support-for-hospitalized-patients-with-chronic-heart-failure/
https://gpcardio.org/en/2026-03-27_individualized-studies-of-triggers-of-paroxysmal-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_individualizing-revascularization-strategy-for-diabetic-patients-with-multivessel-coronary-disease/
https://gpcardio.org/en/2026-03-27_inflammation-in-obesity-related-hfpef/
https://gpcardio.org/en/2026-03-27_inflammatory-and-cholesterol-risk-in-the-fourier-trial/
https://gpcardio.org/en/2026-03-27_influence-of-diabetes-on-sacubitril-valsartan-titration-and-clinical-outcomes-in-patients-hospitalized-for-heart-failure/
https://gpcardio.org/en/2026-03-27_influence-of-microvascular-disease-on-cardiovascular-events-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_influence-of-neprilysin-inhibition-on-the-efficacy-and-safety-of-empagliflozin-in-patients-with-chronic-heart-failure-and-a-reduced-ejection-fraction/
https://gpcardio.org/en/2026-03-27_influence-of-obstructive-sleep-apnea-severity-on-muscle-sympathetic-nerve-activity-and-blood-pressure/
https://gpcardio.org/en/2026-03-27_initial-decline-in-glomerular-filtration-rate-with-finerenone-in-hfmref-hfpef/
https://gpcardio.org/en/2026-03-27_innovation-and-evidence-in-pulmonary-embolism-management/
https://gpcardio.org/en/2026-03-27_instantaneous-wave-free-ratio-versus-fractional-flow-reserve-to-guide-pci/
https://gpcardio.org/en/2026-03-27_integrated-management-of-hiv-diabetes-and-hypertension-in-sub-saharan-africa-inte-africa/
https://gpcardio.org/en/2026-03-27_intensive-blood-pressure-lowering-in-patients-with-acute-cerebral-hemorrhage/
https://gpcardio.org/en/2026-03-27_intensive-blood-pressure-reduction-with-intravenous-thrombolysis-therapy-for-acute-ischaemic-stroke-enchanted/
https://gpcardio.org/en/2026-03-27_intensive-lifestyle-intervention-cardiac-biomarkers-and-cardiovascular-outcomes-in-diabetes/
https://gpcardio.org/en/2026-03-27_intensive-vs-standard-blood-pressure-control-and-cardiovascular-disease-outcomes-in-adults-aged-75-years/
https://gpcardio.org/en/2026-03-27_interplay-of-mineralocorticoid-receptor-antagonists-and-empagliflozin-in-heart-failure/
https://gpcardio.org/en/2026-03-27_intracranial-haemorrhages-vs-stent-thromboses-with-direct-oral-anticoagulant-plus-single-antiplatelet-agent-or-triple-antithrombotic-therapy/
https://gpcardio.org/en/2026-03-27_intrapericardial-left-ventricular-assist-device-for-advanced-heart-failure/
https://gpcardio.org/en/2026-03-27_intravascular-imaging-vs-angiography-guided-complex-pci/
https://gpcardio.org/en/2026-03-27_intravascular-ultrasound-versus-angiography-guided-drug-eluting-stent-implantation/
https://gpcardio.org/en/2026-03-27_intravenous-iron-therapy-for-heart-failure-and-iron-deficiency/
https://gpcardio.org/en/2026-03-27_intravitreal-aflibercept-8-mg-in-diabetic-macular-oedema-photon/
https://gpcardio.org/en/2026-03-27_invasive-versus-conservative-strategy-in-patients-aged-80-years-or-older-with-non-st-elevation-myocardial-infarction-or-unstable-angina-pectoris-after/
https://gpcardio.org/en/2026-03-27_kdigo-2021-clinical-practice-guideline-for-the-management-of-blood-pressure-in-chronic-kidney-disease/
https://gpcardio.org/en/2026-03-27_kidney-disease/
https://gpcardio.org/en/2026-03-27_kidney-failure-risk-projection-for-the-living-kidney-donor-candidate/
https://gpcardio.org/en/2026-03-27_late-thrombotic-events-after-bioresorbable-scaffold-implantation/
https://gpcardio.org/en/2026-03-27_left-atrial-appendage-closure-versus-direct-oral-anticoagulants-in-high-risk-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_left-atrial-appendage-closure-versus-oral-anticoagulants-in-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_left-ventricular-function-congestion-and-effect-of-empagliflozin-on-heart-failure-risk-after-myocardial-infarction/
https://gpcardio.org/en/2026-03-27_levosimendan-in-patients-with-left-ventricular-dysfunction-undergoing-cardiac-surgery/
https://gpcardio.org/en/2026-03-27_lifestyle-glycosylated-hemoglobin-a1c-and-survival-among-patients-with-stable-ischemic-heart-disease-and-diabetes/
https://gpcardio.org/en/2026-03-27_lifestyle-walking-intervention-for-patients-with-heart-failure-with-reduced-ejection-fraction/
https://gpcardio.org/en/2026-03-27_limb-outcomes-with-ticagrelor-plus-aspirin-in-patients-with-diabetes-mellitus-and-atherosclerosis/
https://gpcardio.org/en/2026-03-27_linagliptin-effects-on-heart-failure-and-related-outcomes-in-individuals-with-type-2-diabetes-mellitus-at-high-cardiovascular-and-renal-risk-in-carmel/
https://gpcardio.org/en/2026-03-27_lipid-reduction-variability-and-antidrug-antibody-formation-with-bococizumab/
https://gpcardio.org/en/2026-03-27_lipoprotein-a-pcsk9-inhibition-and-cardiovascular-risk/
https://gpcardio.org/en/2026-03-27_liraglutide-and-cardiovascular-outcomes-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_long-term-effects-following-4-years-of-randomized-treatment-with-atorvastatin-in-patients-with-type-2-diabetes-mellitus-on-hemodialysis/
https://gpcardio.org/en/2026-03-27_long-term-effects-of-patiromer-for-hyperkalaemia-treatment-in-patients-with-mild-heart-failure-and-diabetic-nephropathy-on-angiotensin-converting-enzy/
https://gpcardio.org/en/2026-03-27_long-term-efficacy-of-catheter-ablation-as-first-line-therapy-for-paroxysmal-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_long-term-evaluation-of-dabigatran-150-vs-110-mg-twice-a-day-in-patients-with-non-valvular-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_long-term-mortality-after-blood-pressure-lowering-and-lipid-lowering-treatment-in-patients-with-hypertension-in-the-anglo-scandinavian-cardiac-outcome/
https://gpcardio.org/en/2026-03-27_long-term-outcome-of-targeted-therapy-of-underlying-conditions-in-patients-with-early-persistent-atrial-fibrillation-and-heart-failure/
https://gpcardio.org/en/2026-03-27_long-term-results-of-stenting-versus-endarterectomy-for-carotid-artery-stenosis/
https://gpcardio.org/en/2026-03-27_long-term-safety-and-efficacy-of-achieving-very-low-levels-of-low-density-lipoprotein-cholesterol/
https://gpcardio.org/en/2026-03-27_long-term-survival-following-multivessel-revascularization-in-patients-with-diabetes/
https://gpcardio.org/en/2026-03-27_low-dose-aspirin-for-primary-prevention-of-cardiovascular-events-in-patients-with-type-2-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_low-dose-direct-oral-anticoagulation-vs-dual-antiplatelet-therapy-after-left-atrial-appendage-occlusion/
https://gpcardio.org/en/2026-03-27_low-dose-methotrexate-for-the-prevention-of-atherosclerotic-events/
https://gpcardio.org/en/2026-03-27_low-dose-versus-standard-dose-intravenous-alteplase-in-acute-ischemic-stroke/
https://gpcardio.org/en/2026-03-27_lower-risk-of-heart-failure-and-death-in-patients-initiated-on-sodium-glucose-cotransporter-2-inhibitors-versus-other-glucose-lowering-drugs/
https://gpcardio.org/en/2026-03-27_management-of-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_mandibular-advancement-vs-cpap-for-blood-pressure-reduction-in-patients-with-obstructive-sleep-apnea/
https://gpcardio.org/en/2026-03-27_mechanical-thrombectomy-and-catheter-directed-thrombolysis-in-acute-pulmonary-embolism/
https://gpcardio.org/en/2026-03-27_medi0382-a-glp-1-and-glucagon-receptor-dual-agonist-in-obese-or-overweight-patients-with-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_mediterranean-diet-improves-high-density-lipoprotein-function-in-high-cardiovascular-risk-individuals/
https://gpcardio.org/en/2026-03-27_mediterranean-style-diet-improves-systolic-blood-pressure-and-arterial-stiffness-in-older-adults/
https://gpcardio.org/en/2026-03-27_meta-analysed-numbers-needed-to-treat-of-novel-antidiabetic-drugs-for-cardiovascular-outcomes/
https://gpcardio.org/en/2026-03-27_meta-analysis-of-controlled-studies-on-minimally-interrupted-vs-continuous-use-of-non-vitamin-k-antagonist-oral-anticoagulants-in-catheter-ablation-fo/
https://gpcardio.org/en/2026-03-27_meta-analysis-of-the-effects-of-four-factors-on-the-efficacy-of-sglt2-inhibitors-in-patients-with-hfref/
https://gpcardio.org/en/2026-03-27_metabolic-effects-of-empagliflozin-in-heart-failure/
https://gpcardio.org/en/2026-03-27_metformin-prescription-and-aortic-aneurysm/
https://gpcardio.org/en/2026-03-27_micronutrient-supplementation-to-reduce-cardiovascular-risk/
https://gpcardio.org/en/2026-03-27_moderate-intensity-statin-with-ezetimibe-vs-high-intensity-statin-in-patients-with-diabetes-and-atherosclerotic-cardiovascular-disease-in-the-racing-t/
https://gpcardio.org/en/2026-03-27_modest-salt-reduction-lowers-blood-pressure-and-albumin-excretion-in-impaired-glucose-tolerance-and-type-2-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_mortality-after-coronary-artery-bypass-grafting-versus-percutaneous-coronary-intervention-with-stenting-for-coronary-artery-disease/
https://gpcardio.org/en/2026-03-27_mortality-and-morbidity-in-acutely-ill-adults-treated-with-liberal-versus-conservative-oxygen-therapy-iota/
https://gpcardio.org/en/2026-03-27_mortality-benefit-of-rivaroxaban-plus-aspirin-in-patients-with-chronic-coronary-or-peripheral-artery-disease/
https://gpcardio.org/en/2026-03-27_network-meta-analysis-of-initial-antithrombotic-regimens-after-left-atrial-appendage-occlusion/
https://gpcardio.org/en/2026-03-27_niacin-therapy-and-the-risk-of-new-onset-diabetes/
https://gpcardio.org/en/2026-03-27_no-effect-of-pcsk9-inhibitor-alirocumab-on-the-incidence-of-diabetes-in-a-pooled-analysis-from-10-odyssey-phase-3-studies/
https://gpcardio.org/en/2026-03-27_non-vitamin-k-antagonist-oral-anticoagulants-in-patients-with-atrial-fibrillation-and-valvular-heart-disease/
https://gpcardio.org/en/2026-03-27_obesity-and-effects-of-dapagliflozin-on-cardiovascular-and-renal-outcomes-in-patients-with-type-2-diabetes-mellitus-in-the-declare-timi-58-trial/
https://gpcardio.org/en/2026-03-27_occurence-of-first-and-recurrent-major-adverse-cardiovascular-events-with-liraglutide-treatment-among-patients-with-type-2-diabetes-and-high-risk-of-c/
https://gpcardio.org/en/2026-03-27_off-label-dosing-of-non-vitamin-k-antagonist-oral-anticoagulants-and-adverse-outcomes/
https://gpcardio.org/en/2026-03-27_on-treatment-outcomes-in-patients-with-worsening-renal-function-with-rivaroxaban-compared-with-warfarin/
https://gpcardio.org/en/2026-03-27_one-year-committed-exercise-training-reverses-abnormal-left-ventricular-myocardial-stiffness-in-patients-with-stage-b-heart-failure-with-preserved-eje/
https://gpcardio.org/en/2026-03-27_one-year-mortality-for-bivalirudin-vs-heparins-plus-optional-glycoprotein-iib-iiia-inhibitor-treatment-started-in-the-ambulance-for-st-segment-elevati/
https://gpcardio.org/en/2026-03-27_one-year-outcomes-after-pci-strategies-in-cardiogenic-shock/
https://gpcardio.org/en/2026-03-27_open-label-randomized-trial-comparing-oral-anticoagulation-with-and-without-single-antiplatelet-therapy-in-patients-with-atrial-fibrillation-and-stabl/
https://gpcardio.org/en/2026-03-27_opportunities-of-antidiabetic-drugs-in-cardiovascular-medicine/
https://gpcardio.org/en/2026-03-27_optical-coherence-tomography-compared-with-intravascular-ultrasound-and-with-angiography-to-guide-coronary-stent-implantation-ilumien-iii/
https://gpcardio.org/en/2026-03-27_optimal-timing-of-an-invasive-strategy-in-patients-with-non-st-elevation-acute-coronary-syndrome/
https://gpcardio.org/en/2026-03-27_oral-anticoagulant-therapy-prescription-in-patients-with-atrial-fibrillation-across-the-spectrum-of-stroke-risk/
https://gpcardio.org/en/2026-03-27_oral-anticoagulants-in-atrial-fibrillation-with-valvular-heart-disease-and-bioprosthetic-heart-valves/
https://gpcardio.org/en/2026-03-27_oral-anticoagulation-for-patients-with-atrial-fibrillation-on-long-term-hemodialysis/
https://gpcardio.org/en/2026-03-27_oral-anticoagulation-use-and-left-atrial-appendage-occlusion-in-laaos-iii/
https://gpcardio.org/en/2026-03-27_orthostatic-hypotension-in-the-accord-action-to-control-cardiovascular-risk-in-diabetes-blood-pressure-trial/
https://gpcardio.org/en/2026-03-27_outcomes-after-thrombus-aspiration-for-st-elevation-myocardial-infarction/
https://gpcardio.org/en/2026-03-27_outcomes-and-costs-of-left-atrial-appendage-closure-from-randomized-controlled-trial-and-real-world-experience-relative-to-oral-anticoagulation/
https://gpcardio.org/en/2026-03-27_outcomes-in-anticoagulated-patients-with-atrial-fibrillation-and-with-mitral-or-aortic-valve-disease/
https://gpcardio.org/en/2026-03-27_outcomes-of-patients-with-atrial-fibrillation-and-ischemic-stroke-while-on-oral-anticoagulation/
https://gpcardio.org/en/2026-03-27_oxygen-therapy-in-suspected-acute-myocardial-infarction/
https://gpcardio.org/en/2026-03-27_p2y12-inhibitors-with-oral-anticoagulation-for-percutaneous-coronary-intervention-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_palliative-care-in-heart-failure/
https://gpcardio.org/en/2026-03-27_patent-foramen-ovale-closure-or-anticoagulation-vs-antiplatelets-after-stroke/
https://gpcardio.org/en/2026-03-27_patent-foramen-ovale-closure-or-antiplatelet-therapy-for-cryptogenic-stroke/
https://gpcardio.org/en/2026-03-27_patients-with-atrial-fibrillation-taking-nonsteroidal-anti-inflammatory-drugs-and-oral-anticoagulants-in-the-aristotle-trial/
https://gpcardio.org/en/2026-03-27_pci-strategies-in-patients-with-acute-myocardial-infarction-and-cardiogenic-shock/
https://gpcardio.org/en/2026-03-27_percutaneous-coronary-angioplasty-versus-coronary-artery-bypass-grafting-in-treatment-of-unprotected-left-main-stenosis-noble/
https://gpcardio.org/en/2026-03-27_percutaneous-coronary-intervention-in-patients-with-insulin-treated-and-non-insulin-treated-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_percutaneous-coronary-intervention-in-stable-angina-orbita/
https://gpcardio.org/en/2026-03-27_percutaneous-coronary-intervention-versus-coronary-artery-bypass-grafting-in-patients-with-left-main-disease-with-and-without-diabetes/
https://gpcardio.org/en/2026-03-27_percutaneous-coronary-intervention-vs-coronary-artery-bypass-grafting-in-patients-with-left-main-coronary-artery-stenosis/
https://gpcardio.org/en/2026-03-27_percutaneous-repair-or-medical-treatment-for-secondary-mitral-regurgitation/
https://gpcardio.org/en/2026-03-27_perioperative-management-of-antithrombotic-therapy/
https://gpcardio.org/en/2026-03-27_perioperative-rosuvastatin-in-cardiac-surgery/
https://gpcardio.org/en/2026-03-27_peripheral-artery-disease-and-venous-thromboembolic-events-after-acute-coronary-syndrome/
https://gpcardio.org/en/2026-03-27_periprocedural-outcomes-of-direct-oral-anticoagulants-versus-warfarin-in-nonvalvular-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_pharmacodynamic-comparison-of-prasugrel-versus-ticagrelor-in-patients-with-type-2-diabetes-mellitus-and-coronary-artery-disease/
https://gpcardio.org/en/2026-03-27_physical-activity-and-prognosis-in-the-topcat-trial-treatment-of-preserved-cardiac-function-heart-failure-with-an-aldosterone-antagonist/
https://gpcardio.org/en/2026-03-27_pioglitazone-after-ischemic-stroke-or-transient-ischemic-attack/
https://gpcardio.org/en/2026-03-27_plasma-lipidomic-profiles-improve-on-traditional-risk-factors-for-the-prediction-of-cardiovascular-events-in-type-2-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_polypharmacy-and-the-efficacy-and-safety-of-rivaroxaban-versus-warfarin-in-the-prevention-of-stroke-in-patients-with-nonvalvular-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_postoperative-atrial-fibrillation-and-long-term-risk-of-stroke-after-isolated-coronary-artery-bypass-graft-surgery/
https://gpcardio.org/en/2026-03-27_postprocedural-anticoagulation-after-primary-percutaneous-coronary-intervention-for-st-segment-elevation-myocardial-infarction/
https://gpcardio.org/en/2026-03-27_potassium-nitrate-in-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_pragmatic-trial-of-hospitalization-rate-in-chronic-kidney-disease/
https://gpcardio.org/en/2026-03-27_prasugrel-or-ticagrelor-in-st-segment-elevation-myocardial-infarction-patients-with-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_predictive-models-for-cardiovascular-and-kidney-outcomes-in-patients-with-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_predictive-role-of-atrial-fibrillation-in-cognitive-decline/
https://gpcardio.org/en/2026-03-27_premature-permanent-discontinuation-of-apixaban-or-warfarin-in-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_prevalence-and-prognostic-implications-of-diabetes-with-cardiomyopathy-in-community-dwelling-adults/
https://gpcardio.org/en/2026-03-27_prevalence-of-left-atrial-thrombus-in-anticoagulated-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_prevention-of-bleeding-in-patients-with-atrial-fibrillation-undergoing-pci/
https://gpcardio.org/en/2026-03-27_primary-prevention-implantable-cardioverter-defibrillators-in-patients-with-nonischemic-cardiomyopathy/
https://gpcardio.org/en/2026-03-27_primary-prevention-with-statin-therapy-in-the-elderly/
https://gpcardio.org/en/2026-03-27_prognostic-value-of-variability-in-systolic-blood-pressure-related-to-vascular-events-and-premature-death-in-type-2-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_promotion-of-aerobic-exercise-induced-angiogenesis-is-associated-with-decline-in-blood-pressure-in-hypertension/
https://gpcardio.org/en/2026-03-27_pulmonary-artery-pressure-monitoring-in-chronic-heart-failure/
https://gpcardio.org/en/2026-03-27_quarter-dose-quadruple-combination-therapy-for-initial-treatment-of-hypertension/
https://gpcardio.org/en/2026-03-27_racial-differences-in-quality-of-life-in-patients-with-heart-failure-treated-with-sodium-glucose-cotransporter-2-inhibitors/
https://gpcardio.org/en/2026-03-27_radial-versus-femoral-access-and-bivalirudin-versus-unfractionated-heparin-in-invasively-managed-patients-with-acute-coronary-syndrome-matrix/
https://gpcardio.org/en/2026-03-27_randomized-20-year-infancy-onset-dietary-intervention-life-long-cardiovascular-risk-factors-and-retinal-microvasculature/
https://gpcardio.org/en/2026-03-27_randomized-crossover-trial-of-2-week-ketone-ester-treatment-in-patients-with-type-2-diabetes-and-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_randomized-invitation-to-systematic-nt-probnp-and-ecg-screening-in-75-year-olds-to-detect-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_randomized-trial-of-a-selective-aldose-reductase-inhibitor-in-patients-with-diabetic-cardiomyopathy/
https://gpcardio.org/en/2026-03-27_randomized-trial-of-bilateral-versus-single-internal-thoracic-artery-grafts/
https://gpcardio.org/en/2026-03-27_randomized-trial-of-effect-of-bariatric-surgery-on-blood-pressure-after-5-years/
https://gpcardio.org/en/2026-03-27_randomized-trial-of-endoscopic-or-open-vein-graft-harvesting-for-coronary-artery-bypass/
https://gpcardio.org/en/2026-03-27_rate-control-versus-rhythm-control-for-atrial-fibrillation-after-cardiac-surgery/
https://gpcardio.org/en/2026-03-27_recommendations-for-management-of-clinically-significant-drug-drug-interactions-with-statins-and-select-agents-used-in-patients-with-cardiovascular-di/
https://gpcardio.org/en/2026-03-27_red-meat-consumption-cardiovascular-diseases-and-diabetes/
https://gpcardio.org/en/2026-03-27_reduced-leaflet-motion-after-transcatheter-aortic-valve-replacement/
https://gpcardio.org/en/2026-03-27_reduction-in-ischemic-events-with-ticagrelor-in-diabetic-patients-with-prior-myocardial-infarction-in-pegasus-timi-54/
https://gpcardio.org/en/2026-03-27_reduction-in-total-cardiovascular-events-with-ezetimibe-simvastatin-post-acute-coronary-syndrome/
https://gpcardio.org/en/2026-03-27_reduction-of-low-density-lipoprotein-cholesterol-and-cardiovascular-events-with-proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitors-and-sta/
https://gpcardio.org/en/2026-03-27_relationship-between-hypoglycaemia-cardiovascular-outcomes-and-empagliflozin-treatment-in-the-empa-reg-outcome-trial/
https://gpcardio.org/en/2026-03-27_renal-and-cardiovascular-effects-of-sglt2-inhibition-in-combination-with-loop-diuretics-in-patients-with-type-2-diabetes-and-chronic-heart-failure/
https://gpcardio.org/en/2026-03-27_renal-and-vascular-effects-of-combined-sglt2-and-angiotensin-converting-enzyme-inhibition/
https://gpcardio.org/en/2026-03-27_renal-denervation-in-resistant-hypertension-and-obstructive-sleep-apnea/
https://gpcardio.org/en/2026-03-27_residual-inflammatory-risk-on-treatment-with-pcsk9-inhibition-and-statin-therapy/
https://gpcardio.org/en/2026-03-27_resistant-hypertension/
https://gpcardio.org/en/2026-03-27_restrictive-or-liberal-red-cell-transfusion-for-cardiac-surgery/
https://gpcardio.org/en/2026-03-27_reversing-the-cardiac-effects-of-sedentary-aging-in-middle-age-a-randomized-controlled-trial/
https://gpcardio.org/en/2026-03-27_risk-of-cardiovascular-events-in-patients-with-diabetes-mellitus-on-β-blockers/
https://gpcardio.org/en/2026-03-27_risk-of-stroke-in-chronic-heart-failure-patients-with-preserved-ejection-fraction-but-without-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_risk-of-stroke-or-systemic-embolism-according-to-baseline-frequency-and-duration-of-subclinical-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_rivaroxaban-and-aspirin-in-patients-with-symptomatic-lower-extremity-peripheral-artery-disease/
https://gpcardio.org/en/2026-03-27_rivaroxaban-in-patients-with-heart-failure-sinus-rhythm-and-coronary-disease/
https://gpcardio.org/en/2026-03-27_rivaroxaban-monotherapy-vs-combination-therapy-with-antiplatelets-on-total-thrombotic-and-bleeding-events-in-atrial-fibrillation-with-stable-coronary-/
https://gpcardio.org/en/2026-03-27_rivaroxaban-plus-aspirin-in-patients-with-vascular-disease-and-renal-dysfunction/
https://gpcardio.org/en/2026-03-27_rivaroxaban-plus-aspirin-versus-aspirin-alone-after-endovascular-revascularization-for-symptomatic-pad/
https://gpcardio.org/en/2026-03-27_rivaroxaban-with-or-without-aspirin-in-patients-with-heart-failure-and-chronic-coronary-or-peripheral-artery-disease/
https://gpcardio.org/en/2026-03-27_rivaroxaban-with-or-without-aspirin-in-patients-with-stable-coronary-artery-disease/
https://gpcardio.org/en/2026-03-27_rivaroxaban-with-or-without-aspirin-in-patients-with-stable-peripheral-or-carotid-artery-disease/
https://gpcardio.org/en/2026-03-27_role-of-combination-antiplatelet-and-anticoagulation-therapy-in-diabetes-mellitus-and-cardiovascular-disease/
https://gpcardio.org/en/2026-03-27_routine-revascularization-versus-initial-medical-therapy-for-stable-ischemic-heart-disease/
https://gpcardio.org/en/2026-03-27_routine-stress-testing-in-diabetic-patients-after-percutaneous-coronary-intervention/
https://gpcardio.org/en/2026-03-27_safer-prescribing-a-trial-of-education-informatics-and-financial-incentives/
https://gpcardio.org/en/2026-03-27_safety-and-efficacy-of-bempedoic-acid-to-reduce-ldl-cholesterol/
https://gpcardio.org/en/2026-03-27_safety-and-efficacy-of-dual-vs-triple-antithrombotic-therapy-in-patients-with-atrial-fibrillation-following-percutaneous-coronary-intervention/
https://gpcardio.org/en/2026-03-27_safety-and-efficacy-of-the-european-society-of-cardiology-0-1-hour-algorithm-for-diagnosis-of-myocardial-infarction/
https://gpcardio.org/en/2026-03-27_safety-of-proprotein-convertase-subtilisin-kexin-9-inhibitors/
https://gpcardio.org/en/2026-03-27_safety-of-sodium-glucose-cotransporter-2-inhibitors-drugs-among-heart-failure-patients/
https://gpcardio.org/en/2026-03-27_safety-of-switching-from-a-vitamin-k-antagonist-to-a-non-vitamin-k-antagonist-oral-anticoagulant-in-frail-older-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_screening-for-atrial-fibrillation-in-older-adults-at-primary-care-visits/
https://gpcardio.org/en/2026-03-27_screening-for-atrial-fibrillation-with-electrocardiography/
https://gpcardio.org/en/2026-03-27_screening-for-atrial-fibrillation-with-electrocardiography/
https://gpcardio.org/en/2026-03-27_secondary-prevention-of-cardiovascular-disease-in-patients-with-type-2-diabetes-mellitus/
https://gpcardio.org/en/2026-03-27_semaglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_semaglutide-and-diuretic-use-in-obesity-related-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_semaglutide-and-nt-probnp-in-obesity-related-hfpef/
https://gpcardio.org/en/2026-03-27_semaglutide-and-nyha-functional-class-in-obesity-related-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_serial-measurement-of-high-sensitivity-troponin-i-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes-mellitus-in-the-examine-trial-examinati/
https://gpcardio.org/en/2026-03-27_sglt2-inhibitors-and-cardiac-remodelling/
https://gpcardio.org/en/2026-03-27_sglt2-inhibitors-for-primary-and-secondary-prevention-of-cardiovascular-and-renal-outcomes-in-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_sglt2i-versus-arni-in-heart-failure-with-reduced-ejection-fraction/
https://gpcardio.org/en/2026-03-27_short-term-dabigatran-interruption-before-cardiac-rhythm-device-implantation/
https://gpcardio.org/en/2026-03-27_short-term-exposure-to-air-pollution-increases-mortality-from-hypertension-and-its-multiorgan-complications/
https://gpcardio.org/en/2026-03-27_similar-cardiovascular-outcomes-in-patients-with-diabetes-and-established-or-high-risk-for-coronary-vascular-disease-treated-with-dulaglutide-with-and/
https://gpcardio.org/en/2026-03-27_small-but-mighty/
https://gpcardio.org/en/2026-03-27_smoking-and-heart-failure/
https://gpcardio.org/en/2026-03-27_sodium-glucose-cotransporter-2-inhibitor-effects-on-heart-failure-hospitalization-and-cardiac-function/
https://gpcardio.org/en/2026-03-27_sodium-glucose-cotransporter-2-inhibitors-in-heart-failure-with-reduced-or-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_sodium-glucose-cotransporter-2-inhibitors-in-heart-failure/
https://gpcardio.org/en/2026-03-27_sodium-intake-and-all-cause-mortality-over-20-years-in-the-trials-of-hypertension-prevention/
https://gpcardio.org/en/2026-03-27_spontaneous-coronary-artery-dissection/
https://gpcardio.org/en/2026-03-27_standardized-exercise-training-is-feasible-safe-and-effective-in-pulmonary-arterial-and-chronic-thromboembolic-pulmonary-hypertension/
https://gpcardio.org/en/2026-03-27_statin-use-for-the-primary-prevention-of-cardiovascular-disease-in-adults/
https://gpcardio.org/en/2026-03-27_statins-for-prevention-of-cardiovascular-disease-in-adults/
https://gpcardio.org/en/2026-03-27_stent-thrombosis-in-patients-with-atrial-fibrillation-undergoing-coronary-stenting-in-the-augustus-trial/
https://gpcardio.org/en/2026-03-27_stress-testing-versus-ct-angiography-in-patients-with-diabetes-and-suspected-coronary-artery-disease/
https://gpcardio.org/en/2026-03-27_stroke-in-patients-with-heart-failure-and-reduced-or-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_stroke-risk-in-patients-with-reduced-ejection-fraction-after-myocardial-infarction-without-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_subclinical-device-detected-atrial-fibrillation-and-stroke-risk/
https://gpcardio.org/en/2026-03-27_supervised-exercise-training-for-chronic-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_surgical-versus-percutaneous-coronary-revascularization-in-patients-with-diabetes-and-acute-coronary-syndromes/
https://gpcardio.org/en/2026-03-27_sustained-benefit-of-alternate-behavioral-interventions-to-improve-hypertension-control/
https://gpcardio.org/en/2026-03-27_sustained-efficacy-of-pulmonary-artery-pressure-to-guide-adjustment-of-chronic-heart-failure-therapy/
https://gpcardio.org/en/2026-03-27_sustained-mild-sleep-restriction-increases-blood-pressure-in-women/
https://gpcardio.org/en/2026-03-27_syntax-score-in-patients-with-diabetes-undergoing-coronary-revascularization-in-the-freedom-trial/
https://gpcardio.org/en/2026-03-27_systematic-review-for-the-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection-evaluation-and-management-of-hi/
https://gpcardio.org/en/2026-03-27_systematic-review-for-the-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection-evaluation-and-management-of-hi/
https://gpcardio.org/en/2026-03-27_systematic-review-for-the-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection-evaluation-and-management-of-hi/
https://gpcardio.org/en/2026-03-27_systematic-review-of-sodium-glucose-cotransporter-2-inhibitors/
https://gpcardio.org/en/2026-03-27_systolic-blood-pressure-control-targets-to-prevent-major-cardiovascular-events-and-death-in-patients-with-type-2-diabetes/
https://gpcardio.org/en/2026-03-27_systolic-blood-pressure-reduction-and-risk-of-cardiovascular-disease-and-mortality/
https://gpcardio.org/en/2026-03-27_systolic-blood-pressure-visit-to-visit-variability-and-major-adverse-outcomes-in-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_tafamidis-treatment-for-patients-with-transthyretin-amyloid-cardiomyopathy/
https://gpcardio.org/en/2026-03-27_targeted-therapy-of-underlying-conditions-improves-quality-of-life-in-patients-with-persistent-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_targeted-therapy-of-underlying-conditions-improves-sinus-rhythm-maintenance-in-patients-with-persistent-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_telemonitoring-based-feedback-improves-adherence-to-non-vitamin-k-antagonist-oral-anticoagulants-intake-in-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_temporal-trends-in-adverse-events-after-everolimus-eluting-bioresorbable-vascular-scaffold-versus-everolimus-eluting-metallic-stent-implantation/
https://gpcardio.org/en/2026-03-27_ten-commandments-from-the-2016-esc-eas-guidelines-for-the-management-of-dyslipidaemias/
https://gpcardio.org/en/2026-03-27_ten-commandments-of-2016-esc-guidelines-for-the-management-of-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_ten-year-all-cause-death-after-percutaneous-or-surgical-revascularization-in-diabetic-patients-with-complex-coronary-artery-disease/
https://gpcardio.org/en/2026-03-27_the-2017-american-college-of-cardiology-american-heart-association-clinical-practice-guideline-for-high-blood-pressure-in-adults/
https://gpcardio.org/en/2026-03-27_the-2018-european-heart-rhythm-association-practical-guide-on-the-use-of-non-vitamin-k-antagonist-oral-anticoagulants-in-patients-with-atrial-fibrilla/
https://gpcardio.org/en/2026-03-27_the-2018-european-heart-rhythm-association-practical-guide-on-the-use-of-non-vitamin-k-antagonist-oral-anticoagulants-in-patients-with-atrial-fibrilla/
https://gpcardio.org/en/2026-03-27_the-association-of-coagulation-and-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_the-cardiovascular-effects-of-sglt2-inhibitors-ras-inhibitors-and-arn-inhibitors-in-heart-failure/
https://gpcardio.org/en/2026-03-27_the-ctni-ctnt-ratio-in-myocardial-injury/
https://gpcardio.org/en/2026-03-27_the-effect-of-implantable-cardioverter-defibrillator-in-patients-with-diabetes-and-non-ischaemic-systolic-heart-failure/
https://gpcardio.org/en/2026-03-27_the-effect-of-pcsk9-proprotein-convertase-subtilisin-kexin-type-9-inhibition-on-the-risk-of-venous-thromboembolism/
https://gpcardio.org/en/2026-03-27_the-effectiveness-of-pharmacist-interventions-on-cardiovascular-risk/
https://gpcardio.org/en/2026-03-27_the-impact-of-heart-failure-therapy-in-patients-with-mildly-reduced-ejection-fraction/
https://gpcardio.org/en/2026-03-27_the-impact-of-proprotein-convertase-subtilisin-kexin-type-9-serine-protease-inhibitors-on-lipid-levels-and-outcomes-in-patients-with-primary-hyperchol/
https://gpcardio.org/en/2026-03-27_the-impact-of-urbanisation-on-the-cardiometabolic-health-of-indigenous-brazilian-peoples/
https://gpcardio.org/en/2026-03-27_the-novel-biomarker-based-abc-age-biomarkers-clinical-history-bleeding-risk-score-for-patients-with-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_the-renal-hemodynamic-effects-of-the-sglt2-inhibitor-dapagliflozin-are-caused-by-post-glomerular-vasodilatation-rather-than-pre-glomerular-vasoconstri/
https://gpcardio.org/en/2026-03-27_thin-cap-fibroatheroma-predicts-clinical-events-in-diabetic-patients-with-normal-fractional-flow-reserve/
https://gpcardio.org/en/2026-03-27_three-year-outcomes-with-the-absorb-bioresorbable-scaffold/
https://gpcardio.org/en/2026-03-27_thromboprophylaxis-in-patients-with-fontan-circulation/
https://gpcardio.org/en/2026-03-27_thrombus-aspiration-in-st-segment-elevation-myocardial-infarction/
https://gpcardio.org/en/2026-03-27_ticagrelor-plus-aspirin-for-1-month-followed-by-ticagrelor-monotherapy-for-23-months-vs-aspirin-plus-clopidogrel-or-ticagrelor-for-12-months-followed-/
https://gpcardio.org/en/2026-03-27_ticagrelor-with-or-without-aspirin-in-high-risk-patients-with-diabetes-mellitus-undergoing-percutaneous-coronary-intervention/
https://gpcardio.org/en/2026-03-27_time-course-of-change-in-blood-pressure-from-sodium-reduction-and-the-dash-diet/
https://gpcardio.org/en/2026-03-27_time-to-clinical-benefit-of-dapagliflozin-and-significance-of-prior-heart-failure-hospitalization-in-patients-with-heart-failure-with-reduced-ejection/
https://gpcardio.org/en/2026-03-27_time-to-clinical-benefit-of-dapagliflozin-in-patients-with-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_time-varying-outcomes-with-the-absorb-bioresorbable-vascular-scaffold-during-5-year-follow-up/
https://gpcardio.org/en/2026-03-27_tirzepatide-and-blood-pressure-reduction/
https://gpcardio.org/en/2026-03-27_tirzepatide-reduces-lv-mass-and-paracardiac-adipose-tissue-in-obesity-related-heart-failure/
https://gpcardio.org/en/2026-03-27_transcatheter-bariatric-embolotherapy-for-weight-reduction-in-obesity/
https://gpcardio.org/en/2026-03-27_transcatheter-mitral-valve-repair-in-patients-with-heart-failure/
https://gpcardio.org/en/2026-03-27_trimetazidine-in-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/2026-03-27_two-year-outcomes-of-bioresorbable-vascular-scaffold-versus-drug-eluting-stents-in-coronary-artery-disease/
https://gpcardio.org/en/2026-03-27_two-year-outcomes-of-surgical-treatment-of-moderate-ischemic-mitral-regurgitation/
https://gpcardio.org/en/2026-03-27_two-year-outcomes-of-surgical-treatment-of-severe-ischemic-mitral-regurgitation/
https://gpcardio.org/en/2026-03-27_two-year-outcomes-with-a-magnetically-levitated-cardiac-pump-in-heart-failure/
https://gpcardio.org/en/2026-03-27_uninterrupted-dabigatran-versus-warfarin-for-ablation-in-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_uninterrupted-direct-oral-anticoagulants-vs-uninterrupted-vitamin-k-antagonists-during-catheter-ablation-of-non-valvular-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_uninterrupted-edoxaban-vs-vitamin-k-antagonists-for-ablation-of-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_uninterrupted-vs-interrupted-periprocedural-direct-oral-anticoagulants-for-catheter-ablation-of-atrial-fibrillation/
https://gpcardio.org/en/2026-03-27_use-of-aspirin-to-reduce-risk-of-initial-vascular-events-in-patients-at-moderate-risk-of-cardiovascular-disease-arrive/
https://gpcardio.org/en/2026-03-27_use-of-the-instantaneous-wave-free-ratio-or-fractional-flow-reserve-in-pci/
https://gpcardio.org/en/2026-03-27_valvular-heart-disease-patients-on-edoxaban-or-warfarin-in-the-engage-af-timi-48-trial/
https://gpcardio.org/en/2026-03-27_varenicline-and-ventricular-ectopy-after-myocardial-infarction/
https://gpcardio.org/en/2026-03-27_varenicline-for-smoking-cessation-in-hospitalized-patients-with-acute-coronary-syndrome/
https://gpcardio.org/en/2026-03-27_variables-measured-during-cardiopulmonary-exercise-testing-as-predictors-of-mortality-in-chronic-systolic-heart-failure/
https://gpcardio.org/en/2026-03-27_vegetarian-or-vegan-diets-and-blood-lipids/
https://gpcardio.org/en/2026-03-27_ventricular-tachycardia-ablation-versus-escalation-of-antiarrhythmic-drugs/
https://gpcardio.org/en/2026-03-27_water-conservation-overrides-osmotic-diuresis-during-sglt2-inhibition-in-patients-with-heart-failure/
https://gpcardio.org/en/2026-03-27_wearable-cardioverter-defibrillator-after-myocardial-infarction/
https://gpcardio.org/en/2026-03-27_when-is-it-appropriate-to-stop-non-vitamin-k-antagonist-oral-anticoagulants-before-catheter-ablation-of-atrial-fibrillation-a-multicentre-prospective-/
https://gpcardio.org/en/2026-03-27_will-exercise-advice-be-sufficient-for-treatment-of-young-adults-with-prehypertension-and-hypertension-a-systematic-review-and-meta-analysis/
https://gpcardio.org/en/2026-03-27_win-ratio-analysis-of-transvenous-phrenic-nerve-stimulation-to-treat-central-sleep-apnoea-in-heart-failure/
https://gpcardio.org/en/2026-03-27_withdrawal-of-pharmacological-treatment-for-heart-failure-in-patients-with-recovered-dilated-cardiomyopathy-tred-hf/
https://gpcardio.org/en/2026-03-27_worldwide-trends-in-oral-anticoagulant-use-in-patients-with-atrial-fibrillation-from-2010-to-2018/
https://gpcardio.org/en/2026-03-27_β-blocker-withdrawal-and-functional-capacity-improvement-in-patients-with-heart-failure-with-preserved-ejection-fraction/
https://gpcardio.org/en/about-epccs/
https://gpcardio.org/en/about-ipccs/
https://gpcardio.org/en/cvd-ckd-t2d/
https://gpcardio.org/en/each/
https://gpcardio.org/en/education/
https://gpcardio.org/en/education/cardio-renal-update/
https://gpcardio.org/en/education/cardiovascular-disease-in-special-populations/
https://gpcardio.org/en/education/cardiovascular-update-session-for-primary-care/
https://gpcardio.org/en/education/lipid-management-in-primary-care/
https://gpcardio.org/en/education/managing-cv-risk-in-europe-lessons-from-countries/
https://gpcardio.org/en/education/the-eu-cardiovascular-health-plan/
https://gpcardio.org/en/epccs/
https://gpcardio.org/en/epccs/connected-societies/
https://gpcardio.org/en/esc-congress-2025/
https://gpcardio.org/en/gpcardio/
https://gpcardio.org/en/literature/
https://gpcardio.org/en/literature/
https://gpcardio.org/en/ncd-academy/
https://gpcardio.org/en/resources/
https://gpcardio.org/en/resources/meeting-reports/
https://gpcardio.org/en/resources/practice-guidance/
https://gpcardio.org/en/resources/recent-news/
https://gpcardio.org/en/resources/stratifyhf/
https://gpcardio.org/en/resources/video-updates/
https://gpcardio.org/en/science-updates/
https://gpcardio.org/en/society-updates/
https://gpcardio.org/en/wonca-world-2025/